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ABSTRACT
METAGENOMIC METHODS IN IDIOPATHIC AND IMMUNE DISEASES
Erik Clarke
Frederic D. Bushman
Microbial involvement in disease has been long-established, but only recently has
metagenomics–the study of entire microbial communities–been leveraged in disease
research. Powered by advancements in sequencing technologies, metagenomics has been
used to better understand a wide variety of diseases, especially in the gastrointestinal tract
and other areas with high microbial activity. However, the extreme sensitivity of modern
sequencing and lack of established best practices yields high error rates when used in
settings with low microbial involvement. To realize the potential of metagenomic
sequencing in disease research, we need new high-precision experimental and statistical
methods that reach clinical standards of confidence. In this thesis, I describe our search
for microbial signatures in sarcoidosis, an idiopathic disease with suspected microbial
involvement. Through the use of novel experimental and statistical methods, we were
able to eliminate confounding environmental factors and identify the enrichment of
Cladosporiaceae fungi in sarcoidosis. I next describe a computational method to recover
pathogen genomes from a sample containing mostly host DNA without the use of oversequencing or culturing. This method enables study of cryptic pathogen genomes and the
ability to track genetic variants that may affect virulence or antibiotic resistance. Finally,
I demonstrate the integration of metagenomic sequencing with immune repertoire
sequencing in patients with severe combined immunodeficiency after gene therapy. This
v

study is the first to describe the changes in an immune-naïve microbiome that occur
during the development of a new immune system. We see that the microbiome of these
children shift from an abnormal state to one resembling healthy children in conjunction
with their restored immunities. These studies lay out methods that improve the precision
and utility of metagenomic sequencing for investigating idiopathic and immune
disorders.
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Chapter 1. Introduction
1.1. A brief history of infectious disease
The birth of germ theory
The link between germs and disease seems obvious to us now, but it was actually a
relatively recent (and contentious) development in human knowledge. For most of the
last few thousand years, infectious disease was thought to be spread by miasma, or dirty
air–a hypothesis that helped explain the transmissibility of disease in certain cases, but
failed to translate into effective public health practices. As urbanization spread and
diseases like cholera became more prevalent, water- or sewage-based transmission
patterns played a large role in disease outbreaks. In a now-famous cholera outbreak in
London, a physician named John Snow tracked each disease incident and concluded from
their distribution that they originated from a public water pump. He correctly
hypothesized that the water was contaminated and suggested the agent of contamination
(what he termed “cholera poison”) had a cellular structure and was capable of
reproducing (Snow, 1856).
This hypothesis was part of an emerging “germ theory” of disease based on the
groundbreaking work by Ignaz Semmelweis, Louis Pasteur and others that suggested that
microorganisms, rather than miasma, were the source of infections and infectious disease.
Joseph Lister’s adoption of this theory and promotion of antiseptic practices in surgery
(and the consequent reduction in mortality) showed germ theory’s immediate
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applicability to healthcare, but it was not until the work of Dr. Robert Koch that a
conclusive link between a microbe and a human disease was first established.

Establishing the germ-disease link
Koch was the first to demonstrate the causative link between anthrax and Bacillus
anthracis spores by purifying the bacteria from an affected sheep and using it to infect
mice, who developed anthrax symptoms (Koch & Carter, 1987). Similar experiments
using culture and reinfection lead him to uncover the cause of cholera (Vibrio cholerae)
and tuberculosis (Mycobacterium tuberculosis) and conclusively demonstrate a link
between microbes and infectious disease (Koch & Carter, 1987). This work also set the
foundation for modern culture-based microbiology by improving culture and staining
techniques, but most importantly it led to the development of what are now known as
Koch’s postulates.
Koch’s postulates are guidelines for establishing a causal link between an organism and a
disease (Koch, 1876). They require a) the presence of the organism in all affected
subjects and absence in unaffected subjects; b) the organism must be isolated and
cultured from an affected subject; c) when introduced to an unaffected subject, the
isolated organism should trigger the disease; and d) the identical organism must be
cultured from the newly-diseased subject.
Successes of Koch’s postulates
The establishment of the germ-disease link and Koch’s postulates led to a revolution in
medical microbiology as the causes of some of humanity’s most troublesome diseases
2

were uncovered. In this “Golden Age” of microbiology (Blevins & Bronze, 2010),
bacteria causing diphtheria (1883), tetanus (1884), pneumonia (1886), plague (1894), and
dysentery (1898), as well as many others (Table 1-1), were identified using the principles
behind Koch’s postulates. These discoveries were essential in tracing disease vectors–
often involving fleas, rodents, or sewage–and establishing key elements of modern public
health practices, sanitation, vaccines, and epidemiology. Later, the advent of antibiotics
would provide the means to treat, rather than simply prevent, these diseases.

Year
1877
1878
1879
1880
1881
1882
1883
1883
1884
1885
1886
1887
1888
1892
1894
1896
1898
1900
1903
1906

Disease
Anthrax
Suppuration
Gonorrhea
Typhoid fever
Suppuration
Tuberculosis
Cholera
Diphtheria
Tetanus
Diarrhea
Pneumonia
Meningitis
Food poisoning
Gas gangrene
Plague
Botulism
Dysentery
Paratyphoid
Syphilis
Whooping cough

Organism
Bacillus anthracis
Staphylococcus
Neisseria gonorrhoeae
Salmonella typhi
Streptococcus
Mycobacterium tuberculosis
Vibrio cholerae
Corynebacterium diphtheriae
Clostridium tetani
Escherichia coli
Streptococcus pneumoniae
Neisseria meningitidis
Salmonella enteriditidis
Clostridium perfringens
Yersinia pestis
Clostridium botulinum
Shigella dysenteriae
Salmonella paratyphi
Treponema pallidum
Bordatella pertussis

Discoverer
Koch
Koch
Neisser
Eberth
Ogston
Koch
Koch
Klebs, Loeffler
Nicholaier
Escherich
Fraenkel
Weischselbaum
Gaertner
Welch
Kitasato, Yersin
van Ermengem
Shiga
Schottmüller
Schaudinn, Hoffmann
Bordet, Gengou

Table 1-1 – Discoveries from the ‘golden age’ of bacteriology.
Researchers who discovered the bacterial pathogens behind mankind’s most troubling diseases during the
‘golden age’ of bacteriology. Adapted from Blevins and Bronze (2010).
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1.2. Sequencing and its use in infectious disease
Reaching the limits of culture-based investigations
While the principles behind Koch’s postulates remain the gold standard for identifying
pathogens, it became quickly evident that they were not universally applicable. Koch
himself noticed the presence of M. tuberculosis and V. cholerae in subjects who did not
demonstrate symptoms, violating the first postulate (and establishing the concept of an
asymptomatic carrier). Another persistent complication is the fact that many organisms
are not able to be grown in pure culture, and so the experimental design suggested by
Koch (culture and experimental infection in an animal model) is inapplicable.

There are any number of reasons why a pathogen might be unculturable. For instance,
viruses require specific cellular machinery to reproduce, so culturing on cell-free medium
is impossible. In other cases, the parasite may require coinfection with another organism
for viability (Hepatitis D, for instance (Makino et al., 1987)). This lack of cultivability
does not preclude these organisms from being pathogenic, however, so rigid adherence to
Koch’s postulates would preclude investigators from understanding the diseases caused
by these types of microbes. Adaptation around these limitations lead to the discovery of
the viral causes of yellow fever (Sellards & Hindle, 1928), foot-and-mouth disease
(Loeffier & Frosch, 1897), and polio (Landsteiner K, 1909), among many others. These
advancements demonstrated a growing understanding of the range and diversity of
pathogens.
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One approach toward the investigation of uncultivable pathogens involves the use of
nucleic acid sequencing. Sequence-based methods provide researchers with ways to
identify pathogens regardless of their cultivability. Approaches such as PCR for specific
marker sequences in target organisms are exquisitely sensitive and do not depend on the
viability of the target organism (Josephson, Gerba, & Pepper, 1993). More complex
methods, including whole-DNA shotgun sequencing, are able to recover the entire
genome of a microbe (Anderson, 1981)–or even the genomes of all the microorganisms
in a sample (Segata et al., 2013). These methods have revolutionized microbiology
because they have allowed us to understand more fully the microbial world outside the
petri dish. They have also advanced infectious disease research because their sensitivity
enables us to uncover broad spectrums of pathogens that are not able to be cultured or
otherwise identified.

To formalize the use of sequencing methods in infectious disease research, Fredericks
and Relman published an update to Koch’s postulates (Fredricks & Relman, 1996). The
new guidelines were specifically crafted to avoid the requirement of cultivability in
suspected microbes, as by the time that review was published, countless diseases had
been linked to microbes that cannot be grown in pure culture, such as Whipple’s disease
(the Tropheryma whippelii bacterium, (Relman, Schmidt, MacDermott, & Falkow,
1992)) and Kaposi’s sarcoma (human herpesvirus 8, (Huichen Feng et al., 2007)).
Notable differences between the Koch’s and Relman’s postulates, besides the deemphasis on cultivability, include reframing the presence or absence of the organism as
the enrichment or depletion of nucleic acids from that organism; correlation between
5

sequence- and tissue-based methods such as staining or in situ hybridization; and
identification of plausible methods of virulence (e.g. from related species or identified
virulence factors). The Relman guidelines are significantly less rigid in their formulation
than Koch’s postulates as well. For instance, the requirement of enrichment of nucleotide
signals in affected tissues, rather than absolute presence/absence, reflects the
understanding that many factors unrelated to the disease state may affect the appearance
of microbial DNA, including environmental factors, presence as commensals, and
reagent contamination. In total, Fredricks and Relman’s guidelines are given as flexible
measures that should be assessed holistically, much as Koch’s postulates had to be later
interpreted. The violation of multiple guidelines is possible even in established causal
relationships and the authors emphasize that none of the rules are dogmatic.

Successes using sequencing in etiologic agent detection
Despite the incumbent difficulties in establishing microbe-disease links via sequencing,
there have been a number of notable successes. In 1992, David Relman et al. established
that Whipple’s disease was caused by a previously-unknown microbe by recovering 16S
ribosomal RNA sequences from five patients with Whipple’s disease (Relman et al.,
1992). The organism, termed Tropheryma whippelii, had been seen in affected patients
via microscopy since the first description of the disease but had resisted all culture
efforts. Its association with the disease was thus well-known, and the target sequence was
isolated from all five patients and none of the ten healthy controls. This long-term
association of the cryptic microbe and the disease thus simplified the challenge of
establishing causality. While the precise virulence mechanisms were not described in the
6

1992 paper, they noted that T. whippelii was related to other Actinomycetes bacteria
including pathogenic mycobacteria, and potentially shared disease-causing
characteristics.

In 2008, Feng et al. (H. Feng, Shuda, Chang, & Moore, 2008) identified the virus that
caused Merkel cell carcinoma (MCC) through the use of digital transcriptome subtraction
(Huichen Feng et al., 2007). This technique uses a reverse transcription step to convert
mRNA into cDNA prior to sequencing, and subsequently removes all human-related
cDNA after sequencing. The remaining sequences are checked for homology to potential
organisms of interest: in this case, they already suspected a viral etiology based on
similarities between MCC and Kaposi’s sarcoma. The presence of a transcript with
similarities to existing polyomavirus T antigen allowed the researchers to eventually
uncover the complete viral genome using primer walking; this genome was then used to
check transcripts from other MCC libraries and to design PCR assays to check other
MCC samples. The rates of detection for the new polyomavirus (termed Merkel cell
polyomavirus) were 80% in MCC tissue and 8% in healthy; this represents a significant
shift from the strict presence/absence suggested by Koch’s postulates and a concordance
with Fredricks and Relman’s more flexible guidelines.

More recently, modern metagenomic sequencing was used to identify the pathogen in a
case of neuroleptospirosis that had evaded diagnosis via normal methods (Wilson et al.,
2014). A patient that presented with severe but ambiguous symptoms that were initially
suspected to be neurosarcoidosis after no pathogen was detected. Cerebrospinal fluid
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(CSF) and serum was then shotgun sequenced and analyzed with SURPI, a rapid
pathogen detection pipeline (Naccache et al., 2014). SURPI detected traces of
Leptospiraceae bacteria in the CSF but not in the serum sample with coverage across
3.8% of a leptospira genome. On this basis, the administering physicians decided to treat
the patient for neuroleptospirosis and the symptoms resolved. Leptospiraceae is normally
detected through a serological test for immune response, but due to peculiarities in the
patient’s condition (severe combined immunodeficiency, immunoglobulin
supplementation, etc), the serological challenge was negative. In many ways, the success
in identifying the causative agent in this study was unusually fortuitous. Leptospira are
uncommon enough in a hospital setting not to be likely environmental contaminants and
pathological enough in nature to be a convincing agent. For diseases where the etiologic
agent is uncharacterized, SURPI is not a valid option because it references existing
databases- a flaw intrinsic to most of the current methods of sequence classification. If
the organism was commonly commensal and pathogenic only by merit of a compromised
immune system, it would also be difficult to discern from background levels of that taxa.

Isolating microbial species for genomic analysis
Identifying the etiologic agents in disease is rarely the final step in treatment and
diagnosis. Virulence and pathogenicity of an agent is often linked to species- or strainspecific variations that may be difficult to uncover using normal phylogenetic markers
such as the 16S or ITS rRNA gene sequences (a method explained in more detail below).
To fully understand the pathogenesis of an organism, the complete genome is desirable so
that virulence mechanisms can be determined. However, genomes for most microbial
8

species are still missing or incomplete (Aggarwala, Liang, & Bushman, 2017; Brown et
al., 2015; Hug et al., 2016).

Traditionally the means to get a precise species- or strain-level genome is to isolate and
culture the organism and sequence the isolate, but as described above, such culture-based
approaches are frequently not applicable (Amann et al., 1990; Ghazanfar, Azim, &
Ghazanfar, 2010; Schmeisser, Steele, & Streit, 2007). In the examples outlined
previously, few of the etiologic agents were cultivable in pure culture. One way around
this is to sequence the sample with sufficient depth to achieve complete coverage of the
target genome (along with a large amount of background DNA) (Forde & O’Toole, 2013;
Mardis, 2008). In cases where the genome is especially small, including viruses,
enrichment using PCR techniques are viable options (Minot et al., 2013), but these
techniques are difficult to scale up to normal prokaryotic and eukaryotic genomes.

There have been significant improvements in the ability of shotgun metagenomic
sequencing to identify strain-level variations in microbial communities (Alneberg et al.,
2014; Olm, Brown, Brooks, & Banfield, 2017; Scholz et al., 2016), but these efforts all
face similar pitfalls. For some methods, the complete strain-level genome must be
captured and added to the relevant databases. For instance, programs like StrainPhlAn
(Truong, Tett, Pasolli, Huttenhower, & Segata, 2017) and PanPhlAn (Scholz et al., 2016)
use strain-level reference genomes or species-wide “pangenomes” to profile
metagenomic communities for those known strains. Other approaches that avoid the need
for reference strains, such as CONCOCT (Alneberg et al., 2014) and MetaBAT (Kang,
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Froula, Egan, & Wang, 2015), use pooled metagenomic libraries to construct strain-level
genomes, but face challenges when the organism of interest is especially rare in the
sample and are prone to chimeric misassembly of strain genomes.

Methods such as selective whole-genome amplification (SWGA) (Leichty & Brisson,
2014) allow the enrichment of a target organism in a sample by exploiting differences in
certain sequence motifs along the target and host DNA. By using primers targeted to
sequence motifs more frequently appearing in the target than the background, and a
highly-processive polymerase such as phi29, a researcher can preferentially amplify the
target genome above the background genome. The resulting product is directly
sequenced, but the resulting depth of sequencing required to reach sufficient genome
coverage is substantially reduced. In this way, SWGA makes it easier to get precise
variant-level information about an organism and allows the sequence variants that
underlie its virulence or pathogenicity to be identified. Implementing SWGA for arbitrary
genomes is not trivial, however, as the method described in the original paper for the
selection of effective primer sets is complex and error-prone.

1.3. Metagenomics and the role of the microbiome in disease
The human microbiome
Infectious disease research focuses on the single causative agents of a disease: isolating
and understanding particular pathogens and how to combat them. But it has been known
for some time that the body is home to a vibrant community of microbial life. In 1673,
Antonie Philips van Leeuwenhoek, an acclaimed microscopist, described seeing a variety
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of tiny “animalcules” in samples of pond water and wood–making him the first human to
see a bacteria. In 1861, Joseph Leidy described a flourishing community of microbes
inside the guts of many animals. His work “A flora and fauna within living animals,” is
one of the first descriptions of the microbiome (Leidy, 1861).

We know now that humans share our bodies with trillions of commensal microorganisms,
most of them bacteria and bacteriophage. The exact makeup of these communities vary
by body site and functional characteristics (The Human Microbiome Project, 2012). They
also play key roles in maintaining normal health. For instance, microbes in the gut
facilitate nutrient absorption and digestion (Shreiner, Kao, & Young, 2015), help regulate
the immune system (Arpaia et al., 2013), and may even affect mental state (Rieder,
Wisniewski, Alderman, & Campbell, 2017). Microbes on the skin feed off of shedding
skin cells and help prevent infections (SanMiguel, Meisel, Horwinski, Zheng, & Grice,
2017), and microbes in the genital tract can hinder the acquisition of sexually-transmitted
diseases, such as HIV (Buve, Jespers, Crucitti, & Fichorova, 2014).
The microbiome’s role in maintaining health is also supported by evidence linking
disordered communities to diseases including inflammatory bowel diseases (Gevers et al.,
2014), obesity (Le Chatelier et al., 2013), cardiovascular disease (Z. Wang et al., 2011),
as well as lung and skin disorders (Charlson et al., 2010; Hannigan, Pulos, Grice, &
Mehta, 2015; Kalan et al., 2016; Young et al., 2015). Thus, it is essential to understand
exactly what makes a microbiome “healthy”, what functions they perform in their
respective body sites, and how to alter their composition to prevent or treat disease.
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The advent of metagenomic sequencing
Traditional culture-based techniques are inefficient for metagenomic studies both because
of the relatively small fraction of microbes that are cultivable, and because of the slow,
low-throughput nature of culturing. In addition, phylogenetic characterization using
morphology rather than genetic sequence leads to significant issues: some microbes may
be morphologically identical but separate species, while other microbes may have wildly
different appearances based upon factors such as environment or lifecycle stage– some
fungi belong to two different families depending on their sexual stage due to exactly this
problem (Underhill & Iliev, 2014).

The concept of metagenomic sequencing is basically the adaptation of modern
sequencing technologies to perform surveys of all the microbes present in a sample.
Generally, metagenomic sequencing falls into two approaches: tagged marker sequencing
or whole-genome shotgun sequencing. Tagged marker sequencing uses the amplification
of conserved genetic regions in the microbial targets of interest to gather a picture of the
microbial community in a sample. Examples of this include 16S rRNA sequencing for
bacteria (Weisburg, Barns, Pelletier, & Lane, 1991), and internal transcribed spacer (ITS)
rRNA sequencing for fungi (Schoch et al., 2012). These regions, or “markers,” contain
hypervariable loci flanked by conserved sequences; in bacterial 16S rRNA these are
regions V1-V9, and in eukaryotic ITS rRNA they are ITS1 and ITS2. These
hypervariable loci are under significantly less selective pressure than their surroundings,
and thus accumulate mutations at a higher rate (Gray, Sankoff, & Cedergren, 1984). The
similarity of these regions between two taxa can therefore be used as a proxy for how
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related the taxa are to each other. This also enables the cataloging of these regions into
databases, so that microbes can be linked to their respective version of each marker.
Thus, the amplification and sequencing of these marker regions, followed by similarity
searches in databases like GreenGenes for 16S (DeSantis et al., 2006) and UNITE for
fungal ITS (Koljalg et al., 2005), results in a picture of the bacterial or fungal
communities in a sample. Tagged sequencing is generally low-cost and computationally
straightforward. However, the results are limited to the microbial kingdom of choice, and
even the selection of the variable region in the marker sequence can influence how
sensitive the assay is at retrieving certain families of microbes (Meisel et al., 2016).

The alternative approach to tagged sequencing is known as whole-genome shotgun
sequencing. In this approach, the total nucleic acids in a sample are fragmented and
sequenced without an intermediate amplification step, and the sequencing reads are
matched to a database of microbial sequences (Quince, Walker, Simpson, Loman, &
Segata, 2017). The benefits of this approach are that it is markedly less biased as it can
capture DNA from any organism in the sample, and that it allows partial reconstruction
of the genomes of the organisms, enabling functional characterization. Shotgun
sequencing thus provides a more complete picture of the microbiome, but suffers from
both high costs and analytic difficulty. In many shotgun sequencing experiments, a large
fraction of the reads cannot be assigned to an organism due to the true originator of the
read being absent from databases. And while the sequencing itself is relatively less
biased, the databases themselves are not– some microbial orders are much better
characterized than others (e.g. bacteria versus viruses or fungi).
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As well as helping characterize the function and dysfunction of our microbiomes,
metagenomic sequencing provides a key advancement in germ theory and our ability to
associate microbes with disease. Sequencing the total DNA from healthy and diseased
subjects enables detection of differentially-abundant microbial signatures and potentially
illuminates cryptic agents in diseases that had evaded culture-based detection.
Furthermore, the ability to gather the actual genetic sequences from these microbes
provides the means to understand their pathogenic capacity. Genes that influence
virulence, toxicity and resistance to antimicrobial compounds can be recovered from the
metagenome and may one day form the basis of rapid sequencing-based clinical tests.

Successes linking the microbiome to disease state
Because the gut is the most well-characterized component of the human microbiome,
many of the disease links we’ve associated with changes in the microbiome have to do
with intestinal disorders. In particular, inflammatory bowel diseases such as Crohn’s
disease have been closely linked to dysbiosis in the gut (Huttenhower et al., 2014; Lewis
et al., 2015). Crohn’s disease is a complex disorder involving immune-mediated
inflammation of the gut, especially the proximal colon and ileum. Instead of a single
causative bacterium, researchers have found that structural changes, such as the loss of
certain classes of bacteria and outgrowths of others, can be predictors of Crohn’s disease
onset (Gevers et al., 2014; Haberman et al., 2014). Antibiotic usage and a decrease in
bacterial diversity were also associated with disease severity (Lewis et al., 2015).
Correction of dysbiosis through the use of fecal microbiome transplantation has shown
promising results for Crohn’s disease (Ruben J Colman, 2014).
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Perhaps the most classic case of microbiome dysbiosis correlating with disease is in the
case of Clostridium difficile infection. C. difficile is a commensal microbe in infants but
rarely present in asymptomatic adults (Rousseau et al., 2012). Instead, infection is usually
triggered by exposure to antibiotics, especially long-term use in chronic care facilities
(Britton & Young, 2014). The alteration of the endogenous flora through antibiotics
seems to provide an avenue for C. difficile colonization, and indicates that a “healthy”
microbiome provides resistance to this pathogen. The exact mechanism by which the
microbiome changes from being protective to permissive seems to be related to the
production of bile salts and secondary bile metabolites (Britton & Young, 2014) (Britton
2014). Certain bile acids trigger C. difficile spore germination, and their relative
availability in the microbiome can be increased through the use of antibiotics. Thus, in
the case of C. difficile, we observe a traditional infectious disease that is influenced
strongly by the characteristics of the host gut microbiome.

The use of the dysbiosis as a disease marker has also been demonstrated in preterm
infants for necrotizing enterocolitis (NEC) (Pammi et al., 2017). In a systematic metaanalysis, the authors found that increased levels of Proteobacteria and loss of
Bacteroidetes and Firmicutes characterized a dysbiotic state that was a precursor to NEC.
The correlation between gut bacteria and disease state indicate that microbiome
monitoring and correction through the use of probiotics may be effective treatment for an
otherwise difficult-to-treat disease.
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Beyond disorders involving the gastrointestinal track, dysbiosis in the microbiome has
also been linked to cardiovascular disease and mental health. In one study, Z. Wang et al.
(2011) showed a link between the microbiome and production of phosphatidylcholine, a
dietary metabolite correlated with heart disease. When the researchers dampened the
abilities of the microbiome to produce this metabolite through the use of antibiotics, they
saw a resulting reduction in disease rates, confirming the link between the metabolomic
function of the microbiome and the disease. Recent studies have also linked the
microbiome to mental health, mostly in animal models. For instance, in mice with a
murine version of autism, researchers found they had abnormal microbiomes, and that
addition of certain beneficial bacteria into their gut lead to less autistic-type behaviors
(Hsiao et al., 2013).

The microbiome and the immune system
The links between microbiome structure and disease state often involve the immune
system in some way (e.g. inflammation in IBD-type disorders). This is likely because the
microbiome has been shown to have a regulatory and supplemental effect on the immune
system itself (Arpaia et al., 2013; Atarashi et al., 2013; Kamada & Núñez, 2014). For
instance, Arpaia et al. (2013) demonstrated that metabolites produced by the microbiome
influence the development of pro- and anti-inflammatory regulatory T (Treg) cells. As
these Treg cells are kept in balance in healthy individuals, it suggests that there is a
homeostatic relationship governing the microbiome and immune system that can become
disrupted in cases of dysbiosis.
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The importance of the gut microbiota in maintaining immune homeostasis is in fact well
documented (Guarner & Malagelada, 2003; Renz, Brandtzaeg, & Hornef, 2011; Walker,
2013). For instance, hypersensitivity of the immune system to food-based allergens
appears to be moderated by the gut flora (Guarner & Malagelada, 2003). This effect is
determined by the co-development of the immune system with bacterial colonization of
the gut in early life and takes place on the mucosal interfaces of the intestine and
respiratory tract (Renz et al., 2011). In general, abnormal colonization or immune
conditions early in life can lead to dysbiosis, allergy, or more dangerous immune
disorders (Walker, 2013).

Pitfalls in metagenomic sequencing
Metagenomic sequencing thus has demonstrable clinical value in diagnosing and
understanding a variety of diseases. However, there remain significant experimental and
technological challenges associated with it that hinder clinical adoption. Perhaps most
critical from a diagnostic or etiologic standpoint is modern sequencing’s susceptibility to
false positives. This is partially due to the extreme sensitivity of sequencers and library
preparation methods (Chin, da Silva, & Hegde, 2013). Consequently, both tagged and
shotgun sequencing methods can retrieve extremely rare DNA molecules in a sample,
including ones that are in fact environmental contaminants. Furthermore, sequencing is
agnostic to the viability of the source material: it does not matter if the DNA came from a
living or dead organism (Emerson et al., 2017). Because DNA is stable at room
temperature, sterilization techniques kill contaminating microbes but allow their genetic
material to persist. Microbial DNA has been regularly recovered from laboratory
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reagents, for instance (Kim et al., 2017; Salter et al., 2014) and on sterilized hospital
instruments. The combination of ambient DNA and the sensitivity of sequenced-based
techniques means that it is extremely common to recover contaminant DNA in
metagenomics.

In studies where the goal is to find differentially-enriched microbes in disease, or to
determine whether a pathogen is present or not, this contaminant DNA can be a
significant confounder. A microbial signature may appear enriched in one disease state
over another due only to differences in storage or handling of the samples. Similarly,
sequences from a pathogen may appear in idiopathic disease samples, but only be leftover
DNA clinging to sterilized hospital equipment. To prevent this, the researcher may
employ methods of isolating only DNA from viable organisms such as those described in
Emerson et al. (2017), but in many situations collection and storage procedures could kill
all the microbes in the sample before workup (such as with formalin fixation). In
addition, such methods may bias what is recovered through the metagenomic assay.
Regardless of how the viability of the microbes is considered, it is critical to collect
appropriate reagent and environmental controls to at least understand the contamination
profile of the experiment.

A number of recent studies have described microbial signatures (or even entire microbial
communities) in parts of the human anatomy generally considered to be sterile in healthy
individuals, including the brain, placenta and in semen (Aagaard et al., 2014; Branton et
al., 2013; Hou et al., 2013). Without dismissing these results, it is highly possible that
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these microbes came from any number of contaminating sources, including equipment,
reagents, or nearby high microbial-load areas such as the mouth or genital tract. All too
often, metagenomic studies do not include or show contamination controls, making it
hard to assess the validity of their results. In a follow-up study to confirm the presence of
microbes in placenta, for instance, Lauder et al. (2016) were unable to see any difference
in microbial signatures between placenta samples and reagent controls. Significant work
needs to be done from an experimental standpoint before metagenomic sequencing can
reach clinically-acceptable levels of confidence.

1.4. Motivations for this thesis
In this thesis, I describe a series of studies that apply metagenomic sequencing to
idiopathic and immunological diseases. My aim is to both provide insights into the target
diseases and to demonstrate novel experimental methods that increase sequencing
precision and sensitivity.

New tools for the identification of etiologic agents
In Chapter 2, I present our efforts to find an etiologic trigger for sarcoidosis, an extensive
metagenomic study with broad clinical applications. This is the most comprehensive look
at microbial signatures in sarcoidosis to date: we used 16S, ITS, and virome sequencing,
as well as shotgun sequencing, in 732 distinct samples over three body sites. We
uncovered signatures of a fungus in the Cladosporiaceae family that were enriched in
sarcoidosis lymph nodes across two sample cohorts, suggesting a potential etiologic
trigger. In addition, this study used a novel experimental design and statistical model that
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allowed us to test for enrichment of a microbe in sarcoidosis both in relation to healthy
controls and environmental background simultaneously. This experimental design is
applicable to other clinical sequencing efforts and represents an advancement in lowbiomass metagenomic studies.

Increasing sensitivity of pathogen genomics with swga
In Chapter 3, I describe a new program called swga for designing primers for use in
selective whole-genome amplification (SWGA). SWGA enables the recovery of a target
microbe’s genome from a complex sample, such as a pathogen or parasite from a hostderived sample. However, the effectiveness of the method relies on the selection of
multiple primers that bind preferentially to the target’s genome over the background.
Identifying an effective primer set is a computationally challenging task that originally
involved a lot of manual trial-and-error. The program I describe in this chapter uses an
approach derived from graph theory to establish compatible sets of primers for SWGA
and evaluates their binding characteristics in arbitrary host/target genomes. I demonstrate
how the program and method drastically reduce the sequencing costs for genome
recovery of a variety of targets, including Mycobacterium tuberculosis and Plasmodium
falciparum in humans and Wolbachia pipientis in Drosophila. This program represents
an advancement in infectious disease research by enabling researchers to recover the
genomes of pathogens that are rare or uncultivable in primary samples. These recovered
genomes can then be used to perform population genetics and understand disease
outbreaks, or to model genetic variations that affect pathogenicity.
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Characterizing immune system and microbiome dynamics in SCID
Finally, in Chapter 4, I integrate metagenomic sequencing to characterize the
development of the microbiome in children with severe combined immunodeficiency
(SCID) after gene therapy. These children are born without an immune system, but are
still colonized by microbes, free of interference from the immune system. After gene
therapy, however, the immune system “comes online” and through longitudinal
metagenomic sequencing, we can observe how the new immune system and microbiome
interact. To characterize the developing immune system, we used sequencing of the CD3
region of the TCR-beta locus in circulating T cells. This allowed us to see clonal
outgrowths that suggested the immune system was responding to extant microbiota and
correlate T cell dynamics with microbiome changes. Finally, sequencing of gene therapy
vector integration sites in the same samples allowed us to estimate the minimum number
of cell divisions required to progress from a lymphopoietic progenitor cell to a circulating
T cell, increasing our understanding of human immune development.

Taken together, these studies improve our understanding of microbes in disease, provide
novel methods for identifying and characterizing pathogens, and help understand the
interactions between the immune system and the developing microbiome.

21

Chapter 2. Microbial lineages in sarcoidosis: A metagenomic
analysis tailored for low microbial content samples
The contents of this chapter have been previously published as:
Clarke, E. L., Lauder, A. P., Hofstaedter, C. E., Hwang, Y., Fitzgerald, A. S.,
Imai, I., Biernat, W., Rekawiecki, B., Majewska, H., Dubaniewicz, A., Litzky, L.
A., Feldman, M. D., Bittinger, K., Rossman, M. D., Patterson, K. C., Bushman, F.
D., & Collman, R. G. (2017). Microbial Lineages in Sarcoidosis: A Metagenomic
Analysis Tailored for Low Microbial Content Samples. Am J Respir Crit Care
Med. doi:10.1164/rccm.201705-0891OC

2.1. Abstract
Rationale: The etiology of sarcoidosis is unknown, but microbial agents are suspected as
triggers.

Objective: We sought to identify bacterial, fungal or viral lineages in specimens from
sarcoidosis patients enriched relative to controls using metagenomic DNA sequencing.
Since DNA from environmental contamination contributes disproportionately to samples
with low authentic microbial content, we developed improved methods for filtering
environmental contamination.

Methods: We analyzed specimens from sarcoidosis subjects (n=93), non-sarcoidosis
control subjects (n=72) and various environmental controls (n=150). Sarcoidosis
specimens consisted of two independent sets of formalin-fixed, paraffin-embedded lymph
node biopsies, bronchoalveolar lavage (BAL), Kveim reagent, and fresh granulomatous
spleen from a sarcoidosis patient. All specimens were analyzed by bacterial 16S and
fungal ITS rRNA gene sequencing. In addition, BAL was analyzed by shotgun
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sequencing of fractions enriched for viral particles, and Kveim and spleen were subjected
to whole-genome shotgun sequencing.

Measurements and Main Results: In one tissue set, fungi in the Cladosporiaceae family
were enriched in sarcoidosis compared to non-sarcoidosis tissues; in the other tissue set,
we detected enrichment of several bacterial lineages in sarcoidosis, but not
Cladosporiaceae. BAL showed limited enrichment of Aspergillus fungi. Several
microbial lineages were detected in Kveim and spleen, including Cladosporium. No
microbial lineage was enriched in more than one sample type after correction for multiple
comparisons.

Conclusions: Metagenomic sequencing revealed enrichment of microbes in single types
of sarcoidosis samples, but limited concordance across sample types. Statistical analysis
accounting for environmental contamination was essential to avoiding false positives.

2.2. Introduction
Sarcoidosis is a multisystem disease characterized by an aberrant immune response that
results in inflammation and granuloma formation. Sarcoidosis is believed to have an
antigenic or inflammatory trigger that initiates the immune reaction in a susceptible host
(E. S. Chen & Moller, 2014, 2015; Dubaniewicz, 2013). Several susceptibility genes
have been identified (Fingerlin, Hamzeh, & Maier, 2015; Fischer et al., 2014) but the
trigger remains obscure. Granulomatous inflammation is commonly seen in responses to
microbial agents, as are other features of sarcoidosis immunopathology such as
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oligoclonal CD4 T cell expansion and TH1 polarization (E. S. Chen & Moller, 2014). No
microbial cause has been definitively established for sarcoidosis, but candidates include
species of Mycobacterium (E. S. Chen et al., 2008; Drake et al., 2002; Dubaniewicz et al.,
2007; Song et al., 2005) , as well as fungi (Suchankova et al., 2015) and
Propionibacterium acnes (Ishige, Usui, Takemura, & Eishi, 1999; Nishiwaki et al.,
2004), a common skin bacteria.

The ability to detect rare or unculturable microbes has improved dramatically using deep
DNA sequencing (H. Feng et al., 2008; Greninger et al., 2015; Kelly et al., 2016).
Several studies have applied bacterial 16S rRNA gene sequencing to sarcoidosis, with
differing results (Drake et al., 2002; Richter et al., 1996; Richter et al., 1999). No prior
studies have interrogated fungal lineages with tag sequencing, nor used shotgun
metagenomic sequencing for comprehensive studies of total DNA or purified viral
particles.

We carried out an intensive metagenomic investigation of multiple sarcoidosis sample
sets using 16S rRNA gene sequencing to capture bacteria, ITS sequencing for fungi, and
whole-genome shotgun sequencing to characterize all microbes. Samples (Table 2-1)
include two independent sets of formalin-fixed, paraffin-embedded (FFPE)
granulomatous tissue biopsies from newly-identified sarcoidosis patients and controls
(sets A and B), bronchoalveolar lavage (BAL) from newly diagnosed untreated Stage
II/III sarcoidosis patients and healthy controls (set C), We also interrogated a sample of
the Kveim reagent (set D) (which is made from sarcoidosis-affected spleen and was used
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historically for sarcoidosis diagnosis by intradermal injection and monitoring for
granuloma formation (Klein et al., 1995; Siltzbach, 1961; Teirstein, 1998)), along with
fresh granulomatous spleen from a sarcoidosis patient (set E).

An often-underappreciated feature of sequence-based microbial detection is that at low
levels of true signal, sequences can be dominated by microbial DNA from environmental
sources introduced during sample collection, storage, DNA extraction or other steps
(Lauder et al., 2016; Salter et al., 2014). This particularly confounds analysis of samples
in which the authentic content of microbial DNA is low, such as lung bronchoscopies and
tissue biopsies (Bittinger et al., 2014; Charlson et al., 2011; Robinson, Smith, Sengupta,
Prentice, & Sandin, 2013; Salter et al., 2014). Even with the most careful preparation,
however, there is often no way to eliminate environmental sequences completely, so
further computational and statistical methods must be used to identify contamination.
We thus used extensive environmental sampling and applied novel statistical modeling to
minimize false positive calls. By investigating several independent sample sets and
tissue types, we were able to interrogate whether sarcoidosis-enriched sequences
appeared consistently across sample sets. Some of the results of these studies have been
previously reported in the form of an abstract (EL Clarke, 2015).
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2.3. Methods
2.3.1. Samples collected
2.3.1.1. Archived tissue samples
Two sets of FFPE sarcoidosis and control tissues were analyzed. Set A (from Gdańsk)
were mediastinal lymph nodes showing non-caseating granulomas typical of sarcoidosis,
and negative by staining for acid-fast or fungal elements. Controls were mediastinal
lymph nodes with normal or nonspecific reactive histology. Set B (from Philadelphia)
consisted of mediastinal nodes containing granulomas typical of sarcoidosis and negative
by fungal and acid-fast stain. Controls were histologically normal nodes from cancer
staging procedures. Stored specimens were retrieved and 10um cuts taken under aseptic
conditions. Paraffin block environmental controls were cut concurrently with tissue
specimens. For set A these were matched from the same block as tissue, while for set B
they were not from the same block.

2.3.1.2. Bronchoalveolar lavage (BAL)
BAL fluid (set C) was obtained from subjects undergoing diagnostic bronchoscopy (from
Philadelphia) for suspected new diagnosis of pulmonary sarcoidosis who had chest Xrays consistent with parenchymal (Scadding stage II/III) involvement. Subjects included
here had sarcoidosis confirmed by standard criteria and exclusion of alternative
diagnoses. BAL was performed using standard clinical protocols. Control BAL was
obtained from healthy volunteers who underwent research bronchoscopy (Charlson et al.,
2011). Prior to bronchoscopy, an environmental control (bronchoscope prewash) was
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obtained as previously described (Charlson et al., 2011). BAL and prewash were placed
immediately on ice and stored at -80oC until analysis.

2.3.1.3. Kveim and spleen tissue
An aliquot of Kveim reagent ((Teirstein, 1998); set D) was analyzed that was prepared at
Mt. Sinai Hospital (New York) for clinical diagnostic use as described (Chase, 1961) and
stored under sterile conditions. Sarcoidosis-involved spleen (set E) was obtained from an
individual with longstanding disease (from Philadelphia), previously but not currently
treated, who underwent splenectomy for symptomatic splenomegaly. Tissue was freshly
dissected from the organ and frozen at -80oC. An aliquot of the saline used for tissue
homogenization served as a matched environmental control.

2.3.1.4. Human subjects
Tissue samples were obtained from anonymized tissue archives. Bronchoscopy and
spleen donor subjects provided written informed consent under IRB-approved protocols.

2.3.2. Analysis
2.3.2.1. Sequence analysis of 16S and ITS rRNA gene segments
Details of extraction, amplification, Illumina sequencing and taxonomic assignment are
in Supplement §2.7.1. The bacterial 16S ribosomal RNA gene was amplified using V1V2
primers; this relatively short amplicon was chosen to maximize amplification efficiency
for rare sequences from low microbial biomass samples (Charlson et al., 2011; Charlson
et al., 2012). The fungal ribosomal RNA internal transcribed spacer ITS1 region was
amplified using ITS1F/ITS2 primers (Bittinger et al., 2014; Charlson et al., 2012; Dollive
27

et al., 2012). Sequences were organized into Operational Taxonomic Units (OTUs) at
97% identity. Statistical analysis was carried out at the individual OTU level, and at
genus and family levels.

2.3.2.2. Virome analysis
Virome analysis was carried out on BAL and matched prewash specimens (Abbas et al.,
2016; Young et al., 2015). To enrich for viruses, fluid was pelleted and acellular material
subject to size-exclusion concentration, followed by nuclease treatment to digest nonencapsulated nucleic acids. Nucleic acids were then extracted, and DNA subjected to
whole genome amplification using GenomiPhi. RNA was reverse transcribed to cDNA
and PCR-amplified. Resulting libraries were shotgun-sequenced, reads quality filtered,
then annotated using a custom database we constructed that included all complete
bacterial, fungal, archaeal and viral genomes in RefSeq release 79 (O'Leary et al., 2016).
All non-viral reads were removed from consideration. We found many reads annotated
to viruses later determined to be either from reagents or mis-annotation of human reads
(Abbas et al., 2016), which were therefore excluded. Details are in Supplement §2.7.1.5.

2.3.2.3. Whole genome sequencing
DNA from sarcoidosis spleen tissue and Kveim reagent was subjected to whole genome
sequencing (WGS) on an Illumina HiSeq. Reads were quality-filtered, processed, and
classified using Kraken (Wood & Salzberg, 2014) with our custom database (described
above), with low-complexity regions masked before querying. Details are in Supplement
§2.7.1.6. The analytic pipeline is available at https://github.com/eclarke/sunbeam.
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2.3.2.4. Accessing sequence data
Sequence data are available in the NCBI SRA under BioProject ID PRJNA392272.

2.3.2.5. Statistical analysis
Code and a complete description are in Supplement §2.7.1.7. For sample sets A and C,
which had paired environmental controls, we used the R package lme4 (Douglas Bates &
Walker, 2015) to build a generalized linear mixed effects model (GLMM) to regress the
number of reads of a taxa against the study group (sarcoid/healthy) and sample type
(tissue/environmental control) (Supp. Figure 2-1). Environmental levels of the taxa in
each sample/control pair were captured as a random effect. Enrichment was determined
by the significance and directionality of the coefficient for the study group/sample type
interaction term after fitting the model. For sample set B, which did not have matched
environmental controls, we used the R package DESeq2 (Michael Love, 2014) to
determine enrichment.

Because one could not predict a priori whether a putative sarcoidosis-associated
microbial trigger would be a specific family, genus, species or even OTU, lineages were
tested at the individual OTU level, then aggregated and tested at the species, genus, and
family levels. FDR correction was applied at each taxonomic level, and an FDR p-value
cutoff of 0.1 was considered significant. While interrogating the data at each taxonomic
level increased the risk of type I (false positive) errors, we considered this justified due to
uncertainty over which taxonomic level might be linked to sarcoidosis and the
exploratory nature of the study, and mitigated by the multiple independent sample sets.
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Conversely, since requiring a lineage to reach FDR-corrected significance in multiple
independent sample sets would increase the likelihood of type II errors, we also
considered lineages that were significant after FDR correction in one sample set, but only
significant before FDR correction in other sample sets.

2.4. Results
2.4.1. Sample sets studied
We studied five sets of sarcoidosis samples and controls (Table 2-1). Two (sets A and B)
were archival lymph node tissue from patients undergoing diagnostic biopsy, where the
sarcoidosis tissue studied was histologically confirmed to show granulomas. Set A
included environmental control paraffin blanks matched to the individual tissue block and
analyzed in parallel. BAL (set C) was from patients with untreated pulmonary sarcoidosis
and healthy volunteers. Reasoning that BAL would most likely reveal a microbial trigger
early in the disease course with parenchymal lung involvement, we studied individuals
newly presenting with radiological Scadding stage II/III. Environmental controls
matched to each sample were prewashes of the bronchoscope used to collect the BAL.
We analyzed an aliquot of the Kveim reagent (set D), which is derived from sarcoidosisaffected human spleen and used diagnostically by intradermal injection and monitoring
for granuloma formation. Since this suggests an immunological response to a triggering
antigen (Klein et al., 1995), we hypothesized that Kveim reagent may contain DNA
traces of an etiological microbe. Finally, we tested fresh sarcoidosis-involved spleen (set
E), paired with blank controls processed in parallel to model reagent contamination.
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Sample
Set

A

B

C

Sample Type

Study Group

Samples

Site

Bacteria

Fungi

RNA
viruses

DNA
viruses

Tissue

Sarcoid

45

Gdansk

643

1180

N/A

N/A

Tissue

Control

37

Gdansk

207

236

N/A

N/A

Paraffin only
(paired)

Environmental
control

82

Gdansk

465

1081

N/A

N/A

Blanks

Reagent control

27

Gdansk

74

84

N/A

N/A

Tissue

Sarcoid

30

Philadelphia

5548

2136

N/A

N/A

Tissue

Control

19

Philadelphia

2813

2703

N/A

N/A

Blanks

Reagent control

5

Philadelphia

285

55

N/A

N/A

BAL

Sarcoid

16

Philadelphia

3105

25

1

85

BAL

Healthy subjects

12

Philadelphia

1604

13

1

40

Prewash
(paired)

Environmental
control

24

Philadelphia

823

28

4

99

Blanks

Reagent control

4

Philadelphia

157

22

0

38

Kveim reagent

Sarcoid

1

New York

1725

20

N/A

4

Water

Environmental
control

1

Philadelphia

1035

3

N/A

26

Spleen

Sarcoid

1

Philadelphia

1156

19

N/A

3

Saline wash of
instruments

Environmental
control

2

Philadelphia

408

2

N/A

31

Water

Reagent control

1

Philadelphia

1035

3

N/A

26

D

E

Table 2-1. Sample sets studied.

2.4.2. Set A: Lymph node tissue
Microbial lineages detected in set A by bacterial 16S and fungal ITS rRNA gene
sequencing are shown as stacked bar graphs (Error! Reference source not found.), with d
ominant taxa summarized in Supp. Figure 2-2. Each tissue was paired with a control
paraffin shaving from the same sample block. Lymph node and environmental control
samples are thus plotted side-by-side. In many cases, samples and paraffin controls
appear similar.

To investigate community structures in sarcoidosis and healthy lymph node samples, we
calculated the UniFrac distance between each pair of samples and tested for clustering
using PERMANOVA (Supp. Figure 2-3). Bacterial communities were not significantly
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different between sarcoidosis and non-sarcoidosis tissues (Supp. Figure 2-3A), but fungal
communities were different (Supp. Figure 2-3B; p=0.027, R2=0.037). We then asked
whether community differences might be attributed to differential contamination. We
performed the same PERMANOVA test on paraffin controls from sarcoidosis and nonsarcoidosis samples. No significant difference was detected in bacterial 16S data (Supp.
Figure 2-3C), but we did detect a difference in fungal ITS data (Supp. Figure 2-3D;
p<0.002, R2=0.091). Review of the specimen processing pipeline revealed that most
sarcoidosis samples (31/45) were stored in a different building from non-sarcoidosis
controls. A PERMANOVA test of the effects of storage site on the paraffin
environmental controls revealed a significant effect on fungi (p<0.00001) but not on
bacteria. The environmental fungi responsible for site-specific differences were mostly
of the Aspergillaceae family (negative binomial test, FDR p-value=0.019; Supp. Figure
2-2).

To account for environmental admixture statistically, we designed a generalized linear
mixed model (GLMM) that incorporated each sample’s matched environmental control
(see Methods). In short, this approach uses the matched control to model the background
levels of each taxa. Then, when testing for differential abundance of that taxa, the
background levels are accounted for by a separate term in the regression rather than the
study group term. We used this approach to test for differential abundance between
sarcoidosis and healthy lymph node at the OTU, species, genus, and family level.
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Among fungi, at the family level, Cladosporiaceae (within the Capnodiales order; Error! R
eference source not found.B) was significantly enriched in sarcoidosis (FDR pvalue=0.049). At the OTU level, no individual taxa were significantly enriched after FDR
correction, but two Cladosporium OTUs were significant before FDR correction (p<0.05,
FDR p=1). The Cladosporiaceae fungal lineage is present both in tissue samples and
paraffin blank controls, but is most abundant in sarcoidosis tissue (Error! Reference s
ource not found.C). No bacterial lineages were significantly enriched in sarcoidosis
after accounting for environmental contamination.
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Figure 2-1. Dominant bacterial and fungal orders in lymph node (A).
The major bacterial (A) and fungal (B) orders identified by 16S and ITS rRNA gene sequencing,
respectively, are shown as proportions of total reads. Less common lineages are aggregated under “Other.”
For each pair, the closed symbol (●) indicates the FFPE lymph node sample, while the open symbol (○)
indicates a slice of blank paraffin cut from the same block to serve as an environmental control. Empty
(white) bar charts indicate that the sample was either not available or had no detectable lineages. The
difference in Cladosporiaceae reads between a sample and its environmental control are shown in (C).
Closed circles represent samples with more Cladosporiaceae reads in the sample than the matched
environmental control, while open circles represent samples in which the number of Cladosporiaceae reads
were not greater than in the environment control. The abundances are shown as reads to more accurately
reflect the input to the test, which used raw read counts as input. Normalization between differing
sequencing depths was accounted for by modeling library size as a random effect for each sample (see
Methods).
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2.4.3. Set B: Lymph node tissue
The dominant bacterial and fungal lineages in tissue set B are shown in Figure 2-2, with
rank abundance plots in Supp. Figure 2-4. We compared community structure using
UniFrac and PERMANOVA (Supp. Figure 2-5), and found differences in bacterial (but
not fungal) populations between the sarcoidosis samples and healthy controls (p<0.05).
We then tested for differentially abundant taxa at the OTU, species, genus, and family
levels. Numerous bacterial taxa were significantly enriched in sarcoidosis compared to
control tissues, including three OTUs in the Corynebacterium (order Actinomycetales)
genus (FDR p=1e-5, 0.064 and 0.067, respectively) and four OTUs in the
Rhodocyclaceae family (order Rhodocyclales, FDR p=0.076, 0.003, 2e-05, and 0.005,
respectively). Other sarcoidosis-enriched bacteria were from the Sphinogomonadaceae
family (order Sphingomonadales), the Comamonadaceaea and Oxalobacteraceaea
families (order Burkholderiales), and the Moraxellaceae and Pseudomonadaceae families
(order Pseudomonadales). No fungal lineages were sarcoidosis-enriched in tissue set B
after FDR correction, including Cladosporium (although fungi of this family do appear to
be present in higher levels in the sarcoidosis samples; Supp. Figure 2-4). Given the
absence of paired environmental controls, these results are limited in isolation and serve
mainly for comparison with other sample sets.
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Figure 2-2. Bacterial and fungal lineages in lymph node (B).
The major bacterial (A) and fungal (B) orders identified by 16S rRNA and ITS gene sequencing are shown
as proportions of total reads. Less common lineages are aggregated under “Other.” Seventeen samples
failed to amplify any usable ITS sequences in B and are omitted. Blank paraffin controls matched to each
tissue specimen were not available for these samples.

2.4.4. Set C: Bronchoalveolar lavage
We analyzed DNA from whole BAL for bacteria and fungi using 16S and ITS gene
sequencing (Error! Reference source not found., Supp. Figure 2-6), along with
matched bronchoscope pre-washes. Analysis using UniFrac and PERMANOVA (Supp.
Figure 2-7) showed no significant differences between sarcoidosis and control bacterial
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communities. To identify taxa enriched in sarcoidosis while accounting for
environmental input, we employed the GLMM described above. We found that the
bacterial family Corynebacteriaceae (order Actinomycetales) was enriched in sarcoidosis
before FDR correction, but no taxa were enriched after FDR correction.

Fungal sequences in BAL were sparse (Error! Reference source not found.B), c
oncordant with previous reports on BAL fungal detections (Bittinger et al., 2014).
However, the genus Aspergillus (within the Eurotiales order; Error! Reference source n
ot found.B) was enriched in sarcoidosis (FDR p=0.042).

2.4.4.1. Virome analysis of sarcoidosis BAL
We investigated the lung virome in sarcoidosis by generating virus particle preparations
from acellular BAL and matched prewashes, and deep-sequencing both RNA and DNA.
Initial inspection revealed abundant reads annotated as HHV6/HHV7. These reads
matched human simple sequence repeats (Abbas et al., 2016), and were therefore
removed. We also purged sequences that were present in blank controls and attributable
to viral enzymes used as reagents, and thus likely reagent-derived. Our approach was
designed to detect both DNA and RNA viruses, but we did not recover any RNA viruses
that did not likely originate from reagent contamination.

The majority of remaining viral sequences were phages of the Siphoviridae and
Iridoviridae lineages (Error! Reference source not found.C). The data initially s
uggested a much richer population of viruses in sarcoidosis BAL than healthy controls.
However, viral sequences in the sarcoidosis cohort’s prewash controls were also richer
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than the control cohort’s prewash (Supp. Figure 2-8). This difference is likely because
sarcoidosis subjects underwent bronchoscopy in a clinical endoscopy suite, whereas
healthy volunteers were sampled in a different facility used for research studies. This
suggests that each location contributed a different environmental background of virus
sequences, likely originating in lavage saline or water used to rinse bronchoscopes after
cleaning.

We therefore used the same GLMM approach to account for environmental differences
when testing for enriched viral species. No viruses were sarcoidosis-enriched at any
taxonomic levels tested. Without accounting for environmental input, the enrichment
analysis would have been confounded by differences resulting from bronchoscopy
locations.
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Figure 2-3. Bacterial, fungal and viral lineages in BAL.
The major bacterial (A) and fungal (B) lineages identified by 16S rRNA and ITS gene sequencing, and
viral (C) lineages identified by shotgun sequencing of all nucleic acids in virus particle preparations, are
shown as proportions of the total reads. Data are shown at the order level for A and B, and the family level
for C. Less common lineages are aggregated under “Other.” For each pair, the closed symbol (●) indicates
the BAL fluid, while the open symbol (○) represents the prewash fluid for that scope. Empty (white) bar
charts indicate that the sample was either not collected or had no detectable lineages. Three sample pairs
failed to amplify any ITS sequences and are omitted from B.

2.4.5. Sets D and E: Kveim reagent and sarcoidosis spleen
We analyzed Kveim reagent and fresh spleen from a patient with sarcoidosis. Three
separate pieces of spleen were tested, along with controls to capture sequences from the
environment. Kveim, spleen and controls were subject to 16S and ITS sequence analysis
(Figure 2-4A and B) and also shotgun whole-genome sequencing (WGS) (Figure 2-4C).
WGS yielded mostly human sequences, which were removed; the remaining sequences
queried for microbial annotations.
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The predominant bacteria found by both 16S and WGS were in the Propionibacteriaceae
family (within the Actinomycetales order), and were detected across all samples
including controls. Other ubiquitous taxa included Corynebacteriaceae and
Pseudomonadaceae (of the Actinomycetales and Pseudomonadales orders, respectively).
Some differences were seen between 16S and WGS analysis for other taxa, likely
resulting from the relative representation of sequences within 16S and WGS databases.
No taxa were present only in sarcoidosis samples and not environmental controls.

Fungal detections were sparse in both ITS sequencing and WGS, and inconsistent
between methods. Cladosporiaceae (order Capnodiales) was detected by ITS in one
spleen sample, but not by WGS. This may be due to a paucity of database genomic
sequences for Cladosporiaceae, limiting detection in WGS annotation. There was no
consistent fungal detection in sarcoidosis samples versus controls.

In the WGS data, we initially detected alignments annotated as Toxoplasma gondii in the
Kveim and spleen samples. We also detected reads annotating to an unfinished
Mycobacteria genome. However, these sequences were found to match human
microsatellite simple repeats, and so were judged to be false-positives and removed
(detailed in Supplement §2.7.1.5). This is an issue for WGS data but not for 16S or ITS
analysis, as the untargeted approach allowed capture of low-complexity repeat DNA. The
only viral reads detected were from bacteriophages and were also found in the controls,
and thus inferred to be environmentally-derived.
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Figure 2-4. Microbial lineages in Kveim and sarcoid spleen.
The major lineages in sample sets D (Kveim) and E (sarcoidosis spleen) shown by sequencing. (A) Shows
results from 16S sequencing, (B) shows ITS sequencing, and (C) shows results from whole-genome
shotgun sequencing, after filtering as described in Supplemental Methods §2.7.1.6. Less common lineages
are aggregated under “Other”, including fungal detections in (C).

2.4.6. Shared lineages
No bacterial or fungal lineages were significantly enriched after FDR correction in more
than one sample set. To broaden our search, we examined lineages that were
significantly enriched in one sample set after FDR correction, and queried their
abundance in the other sets. Enriched lineages are summarized in Table 2-2.

41

Sample Set

Kingdom

FDR p < 0.1

non-FDR p < 0.05

Bacteria

None

None

Fungi

Cladosporiaceae

OTU6408 (genus Cladosporium), Cladosporiaceae

Bacteria

Many (113), including
Corynebacterium and
Rhodocyclaceae

Many (252)

Fungi

None

Many (149), including one Cladosporium OTU (OTU7142)

Bacteria

None

OTU 104987 (Family Rhodocyclaceae), OTU 4301737
(genus Porphyromonas), Corynebacterium, Neisseria

Fungi

Aspergillus

Aspergillus

Viruses

None

None

Tissue Set A

Tissue Set B

BAL Set C

Table 2-2. Summary of taxa enriched in sarcoidosis.
Microbial taxa enriched in sarcoidosis lymph node and BAL over healthy controls.

In tissue set A, fungi from the Cladosporiaceae family (order Capnodiales) were
significantly enriched in sarcoidosis when tested as a group. A single Cladosporium
OTU (OTU7142) was enriched in tissue set B before multiple testing correction
(p=0.042), though not the Cladosporiaceae family overall. Cladosporiaceae were
detected but not enriched in sarcoidosis BAL. Finally, abundant Cladosporium reads
were detected in one of three replicate spleen samples via ITS sequencing and not in the
environmental controls, although it was not in WGS of spleen or Kveim.

In tissue set B, three OTUs belonging to the Corynebacterium bacterial genus (order
Actinomycetales) were significantly enriched in sarcoidosis. While no individual
Corynebacterium OTUs were enriched in other sample sets, the Corynebacterium genus
was enriched in sarcoidosis BAL before FDR correction (p=0.02). Corynebacterium
were detected but not sarcoidosis-enriched in tissue set A, and also detected in Kveim
and spleen, as well as environmental controls.
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Also in tissue set B, multiple OTUs in the Rhodocyclaceae (order Rhodocyclales)
bacterial family were significantly enriched. A single Rhodocyclaceae OTU was
enriched in BAL before FDR correction (OTU104987, genus Hydrogenophilus,
p=0.009). No Rhodocyclaceae lineages were detected in tissue set A, but appeared in
both Kveim and spleen as well as controls from sets D and E.

In BAL (set C), fungi in the Aspergillus genus (order Eurotiales) were significantly
enriched in sarcoidosis. Aspergillus was detected in tissue set A, but was not sarcoidosisenriched. Numerous Aspergillus lineages were also detected but not sarcoidosis-enriched
in tissue set B. Aspergillus species were not detected in Kveim or spleen in sets D and E,
but were found in the environmental and blank controls by WGS.

2.5. Discussion
This is the first study to interrogate microbial agents in sarcoidosis using a metagenomic
approach combining bacterial and fungal sequence tag analysis, virome shotgun
sequencing, and whole genome sequencing. We anticipated that a causal microbe would
be present in low abundance, so rigorous consideration of potential contamination would
be critical for distinguishing authentic from environmentally-derived sequences. Our
findings were inconsistent across the five sample sets analyzed (Table 2-1, Table 2-2),
but do provide candidates for further validation, and strongly emphasize the importance
of assessing environmental contamination.
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Cladosporiaceae was significantly enriched in sarcoidosis specimens in tissue set A after
adjustment for environmental admixture and multiple comparisons, and also appeared in
several other sample sets, though not with comparable statistical enrichment. Fungi in the
Cladosporiaceae family are extremely common in the environment (Ezike, Nnamani,
Ogundipe, & Adekanmbi, 2016; Peternel, Culig, & Hrga, 2004), can trigger
hypersensitivity pneumonitis and asthma (Chiba et al., 2009; Tham et al., 2017), and are
capable of eliciting granulomatous inflammation (Robinson et al., 2013; Silva &
Ekizlerian, 1985). This finding may warrant further investigation.

In tissue set B, we detected multiple sarcoidosis-enriched taxa, but interpretation is
limited by the lack of matched environmental controls. Enriched taxa included several
Corynebacterium OTUs, which were also sarcoidosis-enriched before FDR correction in
BAL (set C). Similarly, OTUs annotated as Rhodocyclaceae were significantly enriched
in set B, and enriched before FDR correction in set C. Corynebacterium are particularly
interesting because they are known to elicit granulomatous responses in vivo (Nureki et
al., 2007; Taylor, Paviour, Musaad, Jones, & Holland, 2003), although the association
with sarcoidosis in this study was weak.

In addition to histopathological similarities, mycobacteria have been linked to sarcoidosis
by immunological responses and/or sequence-based detection (E. S. Chen et al., 2008;
Drake et al., 2002; Dubaniewicz et al., 2007; Song et al., 2005). However, we did not find
enrichment of mycobacteria in sarcoidosis. Mycobacteria are difficult bacteria to isolate
DNA from due to tough cell walls. To ensure our methods were robust, we confirmed
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detection via sequencing in known mycobacteria-infected tissue samples, and biological
specimens spiked with avirulent M. tuberculosis (not shown). We also found low levels
of mycobacteria in many samples and environmental controls. This suggests that our
methods are not inherently insensitive to mycobacteria, but that mycobacteria as a group
were not enriched in these sarcoidosis specimens. However, the 16S variable region
amplified, V1V2, cannot distinguish between mycobacterial species, which precludes
detection of species-level differences. We also found that Propionibacterium acnes was
a ubiquitous environmental agent, concordant with other studies (Mollerup et al., 2016),
with no evidence of enrichment in sarcoidosis.

Environmental admixture is an issue in any metagenomic survey and becomes
increasingly important as the amount of authentic microbial content decreases (Salter et
al., 2014). Such sequences can be introduced from specimen collection and storage,
DNA extraction kits, the processing pipeline, or even “barcode error” inherent in Illumina
deep sequencing platforms that can allow low-level bleed-over in the sequencing process
(Lauder et al., 2016). Most importantly in studies comparing subject groups, clinical
samples collected at different times or locations may be contaminated with different
environmental sequences. This is especially problematic when taxa of interest may also
be environmentally present, so simple subtraction of background lineages is
inappropriate. For example, sarcoidosis and healthy BALs were acquired in different
locations and showed different background viromes. For tissue set A, specimen storage
location differed between study groups, which led to enrichment of environmental fungi
in one group and not the other.
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A key component of our approach is the generalized linear mixed model, which enabled
us to capture and control the effects of differential environmental admixture without
losing the ability to test for differential abundance in environmental taxa. In tissue set A,
without accounting for environmental input, a naïve enrichment analysis would have
identified fungal species within the Aspergillus and Penicillium genera as sarcoidosisenriched. The same is true for viruses in BAL (set C), which would have incorrectly
identified greater phage populations in sarcoidosis. The GLMM approach presented here
would enable handling of potential confounding effects of environmental admixture in
microbiome studies generally, and is particularly critical for specimens with low
authentic microbial content, when coupled with appropriate matched environmental
controls for each clinical sample.

Our study has several limitations. We investigated microbes that might be enriched in
sarcoidosis at time of diagnosis, which is the earliest time point feasible, but the time
from actual disease onset is unknown, so an etiological trigger may no longer be present.
Conversely, it is conceivable that microbial enrichment associated with sarcoidosis could
be a consequence of the disease, rather than a cause. Use of samples from distinct
geographic locations would reveal shared lineages, but sarcoidosis triggers may differ
geographically. Additionally, any triggers may not be enriched in sarcoidosis subjects at
all, but may be ubiquitously present, with disease determined mainly by host
susceptibility factors. Although we examined a total of 93 sarcoidosis and 72 nonsarcoidosis specimens, plus 150 environmental controls (for a total of 738 sequencing
reactions) the number of samples in any one set was modest. For the FFPE samples,
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sensitivity may be lessened by damage DNA incurred by during the de-crosslinking step
necessary to undo the formalin fixation (Campos, 2011). For our DNA virus methods,
Genomiphi amplification may introduce bias towards short circular DNA due to rollingcircle amplification, although this bias should be consistent across study groups. Finally,
any primers chosen for tagged sequencing also have inherent biases and may be more
sensitive to some microbes than others (such as with the V1V2 primers and
Mycobacterium species, as discussed previously).

In summary, application of metagenomic sequencing and analytic approaches tailored to
low microbial-biomass samples did not identify a single causative agent but identified
several candidate agents as sarcoidosis-enriched. These include the Cladosporiaceae
fungal family and Corynebacterium bacterial taxa. The modest enrichment and limited
concordance of these candidates in the sample sets precludes our ability to assert any
causal relationship with sarcoidosis, but we believe these candidates may be of interest in
future studies. More broadly, the model we present here increases the power of
metagenomic studies in low microbial biomass samples, such as lung and tissue
specimens, by allowing researchers to account for and test environmental admixture, thus
avoiding potential spurious identifications.
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2.7. Supplemental Material
2.7.1. Supplemental Methods
2.7.1.1. Specimens analyzed
Formalin-fixed paraffin-embedded (FFPE) sarcoidosis and control tissues in set A were
from the Medical University of Gdansk (Gdansk, Poland) and tissue set B were from the
Hospital of the University of Pennsylvania (Philadelphia, PA, USA). Paraffin block
environmental controls targeted a region of the block that did not contain tissue, and were
cut at the same time as the tissue specimens.

Bronchoalveolar lavage (BAL) fluid (set C) was obtained from subjects with Scadding
stage II or III chest X-rays undergoing diagnostic bronchoscopy for a suspected new
diagnosis of pulmonary sarcoidosis. Subjects included here are those in whom
sarcoidosis was confirmed based on standard criteria including transbronchial biopsy
with noncaseating granulomas and exclusion of alternative diagnoses by culture and
stains for fungi and mycobacteria. All subjects were newly-diagnosed and not previously
treated. Non-sarcoidosis control BAL was obtained from healthy volunteers who
underwent research bronchoscopy and have been described previously (Charlson et al.,
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2011). An environmental control (bronchoscope prewash) was obtained prior to each
bronchoscopy by suctioning 10 ml of lavage saline through the scope channel as
previously described (Charlson et al., 2011).

An aliquot of Kveim reagent (set D) was analyzed that was previously prepared at Mt.
Sinai Hospital and validated for clinical diagnostic use as described (Siltzbach, 1961;
Teirstein, 1998).

A specimen of sarcoidosis-involved spleen (set E) was obtained from an individual with
sarcoidosis who underwent splenectomy for symptomatic splenic enlargement.
Histological examination subsequently confirmed granulomatous involvement of the
spleen. Immediately following surgical removal, subcapsular tissue was dissected from
the organ under aseptic conditions, transported in a sterile container on ice, cut into 0.1g
pieces with sterile scissors and forceps under sterile conditions, then snap-frozen and
stored at -80ºC. For analysis, one 0.1g piece of tissue was thawed, cut in thirds with a
sterile scalpel, and each fragment subject to independent DNA extraction and analysis in
parallel. To obtain an appropriate environmental control that reflected both specimen
processing and sequencing steps, prior to tissue dissection an aliquot of saline (that later
served as a vehicle for tissue processing) was used to gently rinse the scalpel that was
subsequently employed for tissue dissection, and this was carried through the DNA
extraction and sequencing pipeline.
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2.7.1.2. DNA purification
DNA from paraffin-embedded, formaldehyde-fixed tissue samples (10um slices) was
extracted using the Qiagen GeneRead DNA FFPE Tissue kit following manufacturer’s
recommendations, except with the addition of a 10 minute, 95ºC incubation step during
proteinase digestion to maximize DNA yield from hard-to-lyse fungi and other microbes,
and increase DNA yield. For 16S and ITS sequencing, DNA from 1.8 ml of
unfractionated BAL fluid and the corresponding scope prewashes was isolated using the
PowerSoil DNA kit (MoBio, Carlsbad, CA), and included an additional 10 min, 95ºC
incubation step as above. DNA and RNA isolation for virome sequencing is described
below. For spleen, three sections of approximately 0.03g each were dissected from a
larger 0.1g piece under sterile conditions, and DNA was isolated using the Qiagen
QIAamp Pathogen UCP Mini kit. For Kveim reagent, 200ul aliquots of material were
spun down at 10,000 RPM in a tabletop centrifuge for 10 minutes and the supernatant
was discarded. The pellet was resuspended in SM buffer and extracted using the Qiagen
QIAamp Pathogen UCP Mini kit. All extractions were performed in a BSL2+ hood after
the workspace was treated with DNA remover and UV irradiation to remove
environmental contamination. DNA was stored at -20oC.

2.7.1.3. Sequence analysis of 16S and ITS rRNA gene segments
Bacterial 16S ribosomal DNA was amplified using primers for the V1V2 16S region
(Supp. Table 2-1) and PCR conditions as described previously (Charlson et al., 2012;
Lauder et al., 2016). Each PCR reaction was carried out in duplicate or triplicate in 25ul
reactions and pooled before sequencing. The PCR reactions were conducted using
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AccuPrime Taq DNA Polymerase from Invitrogen and the pooled amplicons were
sequenced on an Illumina MiSeq. Resulting sequence reads were processed using the
QIIME 1.91 workflow (Caporaso, Kuczynski, et al., 2010). In brief, the reads were
clustered into OTUs with 97% sequence similarity using UCLUST (Edgar, 2010) and
aligned to full-length 16S sequences using pyNAST (Caporaso, Bittinger, et al., 2010).
Taxonomic ranks were assigned using RDP Classifier (G. P. Wang, Ciuffi, Leipzig,
Berry, & Bushman, 2007) with minimum 50% confidence.

The fungal ITS1 region was amplified using ITS1F and ITS2 primers ((Dollive et al.,
2012; Gardes & Bruns, 1993), Supp. Table 2-1), with each sample individually barcoded
using Golay barcodes. The PCR reactions were carried out in duplicate or triplicate with
4ul of template, 0.4 ul AccuPrime Polymerase, 3ul of 10uM forward primer, 3ul of 10uM
reverse primer, 2.5 ul Buffer II, and 12.1 ul PCR-grade water. The reactions were
conducted using cycling parameters as follows: 94oC initial denaturation for 3 minutes;
94oC for 45s, 56oC for 60s, 72oC for 90s (35 cycles); 72oC final extension for 10 minutes.
The individual replicates were bead purified using Agencourt AMPure XP beads (1:1
ratio), and then purified a second time with a 0.8 ratio to remove excess primer dimers.
Amplicon concentration was assessed using Picogreen and product size checked on a
BioAnalyzer. The final products were pooled for sequencing and bead-purified again at a
0.8 ratio to remove further primer dimers. The sequencing was performed on an Illumina
Miseq. After sequencing, the reads were processed using PIPITS (Gweon et al., 2015).
Taxonomy was assigned using BROCC (Dollive et al., 2012) and all subsequent analysis
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was performed in R. All synthetic DNA sequences used in this study are in Supp. Table
2-1.

2.7.1.4. Virome analysis
To enrich for viruses in BAL and matched prewash specimens, the following steps were
used: 1.8ml of BAL fluid was pelleted at 960g for 10 min and the acellular supernatant
material then subjected to size exclusion concentration (100 kDa; Amicon). The filtered
material was then nuclease treated to digest non-encapsulated nucleic acids. Nucleic
acids were extracted, DNA subjected to whole genome amplification using GenomiPhi,
and RNA was transcribed to cDNA and PCR-amplified. Details of these methods have
been previously described (Abbas et al., 2016). The resulting libraries were shotgun
sequenced on an Illumina HiSeq 2500 using the Nextera XT DNA Library Preparation
Kit (Illumina, San Diego, CA) with dual-indexed barcodes, and reads were quality
filtered using Trimmomatic (Bolger, Lohse, & Usadel, 2014).

Human reads were filtered by removing any that mapped to the human genome
(GRCh38). Remaining reads were annotated using Kraken (Wood & Salzberg, 2014)
using a custom database that included all complete bacterial, fungal, archaeal and viral
genomes available in RefSeq release 79 (O'Leary et al., 2016). All non-virus reads were
removed from consideration. We found many reads annotated to viruses later determined
to be either from reagents or otherwise spurious, including mis-annotation of human
reads, as we have previously reported (Abbas et al., 2016). We excluded the following
species: Enterobacteria phage M13, Enterobacteria phage T7, Enterobacteria phage phiX-
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174 sensu lato, Bacillus phage phi29, and Pseudomonas phage phi6, human herpesvirus 6
and 7, and Shamonda virus.

2.7.1.5. Additional quality control issues
To minimize the impact of batch effects (Salter et al., 2014), a single lot of DNA
extraction kits were used for all samples of a given type (including sarcoidosis, nonsarcoidosis, and evironmental controls), and all samples of each set were combined and
sequenced in a single sequencing run. Because fixation can partially degrade DNA and
subsequent downstream analysis (Campos, 2011), we used the Qiagen GeneRead FFPE
kit, which includes an enzyme to correct C->T mutations that may occur. This kit does
not address increased DNA fragmentation from fixation, but we expect these effects to be
minimal due to the small length of the target V1V2 and ITS1 regions in 16S and ITS
sequencing.

2.7.1.6. Whole genome sequencing
Sarcoid spleen tissue and Kveim reagent were analyzed using metagenomic whole
genome shotgun sequencing. DNA was extracted using the Qiagen Ultraclean Pathogen
(UCP) Mini kit following its recommendations for DNA isolation from tissue samples.
Metagenomic sequencing was carried out on an Illumina HiSeq 2500 using the Nextera
XT DNA Library Preparation Kit (Illumina, San Diego, CA) with dual-index barcodes.
The reads from the metagenomic sequencing were then processed in the following steps:
1) reads were quality-filtered, paired and adapter-trimmed using Trimmomatic (Bolger et
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al., 2014); 2) human and phiX reads (used in sequencing library prep) were removed
using bwa (Li & Durbin, 2009), and 3) reads were classified using Kraken (Wood &
Salzberg, 2014) with a custom database built from all genomic sequences from RefSeq
(release 79, (O'Leary et al., 2016)), with low-complexity regions masked before
querying. The complete pipeline is available at https://github.com/eclarke/sunbeam.

In initial analysis, reads containing short sequence repeats from human DNA were
annotated to various species including Toxoplasma gondii and Mycobacterium spp. The
short repeat sequences in these reads were also present in some draft genomes used to
build our database, and were sufficiently complex to avoid masking by the NCBI dust
program (Camacho et al., 2009) used on all database sequences. These annotations were
judged to be false positives based on their presence in the human genome and the lack of
any other reads aligning to Toxoplasma gondii and Mycobacterium spp.. To prevent
further false positives, we used the RepeatMasker program (Smit, 2013-2015) to mask
these repeat regions and re-ran the classification. The results presented here reflect
classification after repeat masking.

2.7.1.7. Statistical analysis
In order to compare study group samples while accounting for the environmental
controls, we developed a generalized linear mixed effects model (GLMM) with the
following design. The presence or absence of a taxa was modeled using a binomial link
function, and the fixed effects were study group (sarcoidosis or healthy) and sample type
(BAL vs prewash, or FFPE vs blank paraffin). The random effects were the grouping pair
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(i.e. the sample with its matched control) plus random effect for each individual sample.
The inclusion of this latter random effect helped control overdispersion (Harrison, 2014)
and account for varying library size between samples. The model was built using the
‘glmer’ function in the R package lme4 (Douglas Bates & Walker, 2015). To determine if
a taxon was significantly enriched, we looked at the significance and directionality of the
coefficient on the study group and sample type interaction term. Specifically, the
coefficient had to be positive in the sarcoidosis and non-environmental direction to be
considered enriched in sarcoidosis over both the healthy and environmental background.
The significance of the interaction coefficient was measured both by testing the model
with and without the interaction term via ANOVA. The significance of the interaction
coefficient was measured by ANOVA, comparing to an alternative model without the
interaction term. Taxa appearing in less than 10% of the samples, for which the model
failed to fit, or which had a negative interaction coefficient after fitting were discarded
from further consideration. P-values from the remaining taxa were subjected to multiple
testing correction using the Benjamini-Hochberg method (Benjamini & Hochberg, 1995).
We set our FDR-corrected p-value threshold at 0.10 to prioritize finding potential hits.

For tissue cohort B, we did not have matched environmental controls, and so the GLMM
specified above was unnecessary. Instead, we used the R package DESeq2 (Michael
Love, 2014) to assess enrichment of a taxa in sarcoidosis samples over healthy controls.
DESeq2 uses a negative binomial distribution to fit taxon abundance in samples in a
generalized linear model, but cannot model random mixed effects. The package provides
p-value and multiple testing correction automatically, and for consistency we used the
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same FDR threshold of 0.1. DESeq2 is one of the currently recommended methods for
testing for differentially abundant taxa by the QIIME developers (Caporaso, Kuczynski,
et al., 2010).

In both the GLMM or the DESeq2 approach, we tested at a hierarchy of taxonomic ranks.
After testing each individual OTU, we collapsed the counts according to species so that
the reads of all OTUs belonging to the same species were summed together. We then
tested each species from the same model, and repeated this process for genus and family
level ranks. Our rationale for this was that etiologic agents may be multiple species or
taxa within a higher group- e.g. a family of molds, or a number of closely related
bacterial species.

2.7.1.8. Data availability
The code used for all analysis, including the specific model formulation, is available
online at https://github.com/eclarke/sarcoid-microbiome-paper. Post-processed sequence
data (after quality control, OTU formation, and taxonomic assignment) is archived at
https://zenodo.org/record/825276. Raw sequence reads are archived with NCBI under
BioProject PRJNA392272.
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2.7.2. Supplemental Figures
Read counts for Taxon X
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Density
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Supp. Figure 2-1. Illustration of statistical approach.
Each taxa is considered individually. Background reads of the taxa from its environmental control (blue)
are considered with the reads detected in the paired sample (red). The reads from a taxon are modeled using
a binomial distribution link function in a generalized linear mixed model, and enrichment is determined by
the magnitude and direction of the regression term corresponding to sarcoidosis samples when contrasted
with healthy samples and environmental controls. A positive coefficient for the sarcoidosis + sample type
interaction term indicates enrichment of that taxa relative to environment and healthy controls; statistical
significance is assessed via ANOVA with a model lacking the interaction term between sample type and
study group. The code describing the model exactly is available online at
https://github.com/eclarke/sarcoid-microbiome-paper.
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Supp. Figure 2-2. Dominant taxa in tissue samples (Set A).
The dominant bacterial taxa (A) and fungal taxa (B) in sample set A are shown in the form of their median
abundance in all samples (white lines) and 95% median confidence intervals (surrounding boxes). Lineages
are grouped by their most specific taxonomic rank available. A differential enrichment of Aspergillus fungi
is visible in the sarcoidosis samples and environmental controls, and enrichment of Cladosporiaceae is
apparent in sarcoidosis lymph node.
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Supp. Figure 2-3. Community differences in tissue samples (Set A).
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Distances between all pairs of samples were generated using generalized UniFrac (J. Chen et al., 2012;
Lozupone, Lladser, Knights, Stombaugh, & Knight, 2011) with an alpha parameter of 0.5. Principle
Coordinate Analysis (PCoA) plots show relationships between bacterial communities in lymph nodes (A),
fungal communities in lymph nodes (B), bacterial communities in blank paraffin (C), and fungal
communities in blank paraffin (D). There were no significant differences in bacterial communities between
sarcoid and healthy lymph node samples or their matched paraffin controls. There were significant
differences in the fungal communities of sarcoid and healthy lymph node samples (p < 0.05), but these
differences were also present in the matched paraffin controls (p < 0.01).

Supp. Figure 2-4. Dominant taxa in tissue samples (Set B).
The dominant bacterial taxa (A) and fungal taxa (B) in sample set B are shown in the form of their median
abundance in all samples (white lines) and 95% median confidence intervals (surrounding boxes). Lineages
are grouped by their most specific taxonomic rank available.

60

Supp. Figure 2-5. Community differences in tissue samples (Set B).
Distances between all pairs of samples were generated using generalized UniFrac (alpha=0.5). Principle
Coordinate Analysis (PCoA) plots showing relationships between bacterial communities (A) and fungal
communities (B) in lymph node samples in sample set B. Significant differences were found in the bacterial
communities of sarcoidosis and healthy lymph node (p < 0.05).
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Supp. Figure 2-6. Dominant taxa in BAL samples (Set C).
The dominant bacterial taxa (A), fungal taxa (B) and viruses (C) in sample set C are shown in the form of
their median abundance in all samples (white lines) and 95% median confidence intervals (surrounding
boxes). Lineages are grouped by their most specific taxonomic rank available.
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Supp. Figure 2-7. Community differences in BAL samples (Set C).
Distances between all pairs of samples were generated using generalized UniFrac (alpha=0.5). Principle
Coordinate Analysis (PCoA) plots showing relationships between bacterial communities in BAL and
prewash samples from set C. No significant differences were found between sarcoidosis and healthy BAL
(panel A) or their corresponding prewash (panel B).
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Supp. Figure 2-8. Differences in prewash viral populations.
Viral populations differ between bronchoscope prewash samples taken just before bronchoscopy of healthy
volunteers (left panel) and sarcoidosis subjects (right panel). Rows indicate the viruses detected, columns
are separate samples.
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2.7.3. Supplemental Tables
Supp. Table 2-1. Oligonucleotide sequences used in Chapter 2.
Name

Illumina
MiSeq 16S
V1-V2
Amplification
and
Sequencing
Primers

Forward
PCR
amplification
primer

5'AATGATACGGCGACCACCGAGATCTACACXXXXXXXXXXXX-TATGGTAATT-GTAGAGTTTGATCCTGGCTCAG-3'

Reverse
PCR
amplification
primer

5'-CAAGCAGAAGACGGCATACGAGATXXXXXXXXXXXX-AGTCAGTCAG-CCTGCTGCCTCCCGTAGGAGT-3'

Forward
sequencing
primer
Reverse
sequencing
primer

Illumina
MiSeq ITS1F
and ITS2
Amplification
and
Sequencing
Primers

5'-TATGGTAATT-GTAGAGTTTGATCCTGGCTCAG-3'
5'-AGTCAGTCAG-CCTGCTGCCTCCCGTAGGAGT-3'

Forward
PCR
amplification
primer

5'AATGATACGGCGACCACCGAGATCTACACXXXXXXXXXXXX-TGCGGCCTGC-GTCTTGGTCATTTAGAGGAAGTAA-3'

Reverse
PCR
amplification
primer

5'-CAAGCAGAAGACGGCATACGAGATXXXXXXXXXXXX-AGTCAGTCAG-CCGCTGCGTTCTTCATCGATGC-3'

Forward
sequencing
primer
Reverse
sequencing
primer
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Sequence

5'-TGCGGCCTGC-GTCTTGGTCATTTAGAGGAAGTAA-3'
5'-AGTCAGTCAG-CCGCTGCGTTCTTCATCGATGC-3'

Components
5' Illumina
adapter, 12-base
Golay barcode
(X's), forward
pad*, linker**,
27F forward
primer
Reverse
complement of 3'
Illumina adapter,
12-base Golay
barcode (X's),
reverse pad,
linker, 338R
reverse primer
Forward pad,
linker, 27F
forward primer
Reverse pad,
linker, 338R
reverse primer
5' Illumina
adapter, 12-base
Golay barcode
(X's), forward
pad*, linker**,
ITS1F primer
Reverse
complement of 3'
Illumina adapter,
12-base Golay
barcode (X's),
reverse pad,
linker, ITS2
primer
Forward pad,
linker, ITS1F
primer
Reverse pad,
linker, ITS2
primer

Chapter 3. Swga: A primer design toolkit for selective whole
genome amplification
The contents of this chapter have been previously published in:
Clarke, E. L., Sundararaman, S. A., Seifert, S. N., Bushman, F. D., Hahn, B. H.,
& Brisson, D. (2017). swga: a primer design toolkit for selective whole genome
amplification. Bioinformatics, 33(14), 2071-2077.
doi:10.1093/bioinformatics/btx118

3.1. Abstract
Motivation: Population genomic analyses are often hindered by difficulties in obtaining
sufficient numbers of genomes for analysis by DNA sequencing. Selective wholegenome amplification (SWGA) provides an efficient approach to amplify microbial
genomes from complex backgrounds for sequence acquisition. However, the process of
designing sets of primers for this method has many degrees of freedom and would benefit
from an automated process to evaluate the vast number of potential primer sets.

Results: Here, we present swga, a program that identifies primer sets for SWGA and
evaluates them for efficiency and selectivity. We used swga to design and test primer sets
for the selective amplification of Wolbachia pipientis genomic DNA from infected
Drosophila melanogaster and Mycobacterium tuberculosis from human blood. We
identify primer sets that successfully amplify each against their backgrounds and describe
a general method for using swga for arbitrary targets. In addition, we describe
characteristics of primer sets that correlate with successful amplification, and present
guidelines for implementation of SWGA to detect new targets.
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Availability and Implementation: Source code and documentation are freely available on
https://www.github.com/eclarke/swga. The program is implemented in Python and C and
licensed under the GNU Public License.

3.2. Introduction
Selective whole-genome amplification (SWGA) provides a means of obtaining sufficient
numbers of genomes from a target organism to perform whole-genome sequence
analysis, even in the presence of overwhelming DNA from other organisms (Leichty &
Brisson, 2014). Difficulties in isolating a target of interest are common in microbial
population genomics, which requires acquiring adequate genomic DNA from a target
while limiting the amount of non-target DNA (Mardis, 2008). Often, the genomes of
interest represent only a fraction of a percent of the total nucleic acids in a sample, and so
direct sequencing is inefficient and expensive. Laboratory culture of the target microbe is
the traditional solution, but many microbes replicate poorly or not at all in in vitro
conditions (Amann et al., 1990; Ghazanfar et al., 2010; Schmeisser et al., 2007).

SWGA allows sequence acquisition without culture of the target organism or extensive
purification of target DNA. It achieves this by preferentially amplifying the target
genome using a set of selective primers and phi29 polymerase-based multiple
displacement amplification (MDA) (Dean et al., 2002; Leichty & Brisson, 2014). Since
its introduction, this method has been used to study Wolbachia pipientis in Drosophila
melanogaster (Leichty & Brisson, 2014), and to understand the evolution and drug
resistance of Plasmodium falciparum (Guggisberg et al., 2016; Oyola et al., 2016;
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Sundararaman et al., 2016) and Plasmodium vivax (Cowell et al., 2017). Further
applications of SWGA to population genomics may help reconstruct epidemic
transmission patterns, characterize patterns of inter-host viral transmission, detect escape
from antimicrobial agents, and delineate the evolutionary dynamics of immune escape
(Hume, Lyons, & Day, 2003; Luikart, England, Tallmon, Jordan, & Taberlet, 2003;
Martínez et al., 2012; Nelson et al., 2008; Nunes et al., 2012; Stack, Murcia, Grenfell,
Wood, & Holmes, 2012).

Implementation of SWGA has been complicated by the difficulty in identifying an
effective set of selective primers, as there are many constraints and degrees of freedom in
the composition of potential primer sets. These primers must reflect DNA sequence
motifs common in the target genome but rare in the background DNA. They also must
have binding sites sufficiently near each other to enable the branching and displacement
actions of the phi29 polymerase that are essential for MDA. A previously published
method used a set of Perl scripts (Leichty & Brisson, 2014) to identify primers with the
highest ratio of binding frequencies in the target genome versus the background DNA.
However, choosing a set by the above method is suboptimal: for one, the primers may
form heterodimers with each other or homodimers with themselves; they may be
individually selective but in aggregate bind too frequently to the background DNA; or,
they may bind to the target’s telomeric or mitochondrial DNA, and not be sufficiently
evenly distributed across the genome. There are aspects of the primer sets that have an
unknown effect on the efficiency of the reaction, including the annealing and melting
temperature of the primer sequences, the evenness of the binding sites across the target
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genome, and the density of binding sites. The Perl scripts mentioned above are unable to
evaluate many of these criteria, requiring extensive manual effort and trial-and-error to
create workable designs.

Here we present swga, a program that identifies selective primer sets for a given target
genome and background. swga evaluates all potential primer sequences and forms sets of
valid primers that meet the above criteria. It automatically calculates a variety of metrics
for each set that potentially affect the efficacy and selectivity of the reaction. These sets
are then are ranked and presented to the user, enabling the selection of primer sets most
likely to succeed. Nearly all operating parameters of the program are user-specifiable but
initialized with reasonable defaults based on the target and background genomes selected,
reducing the work needed to get started.

We demonstrate the use of swga to design primer sets and test them on two biological
systems: Wolbachia pipientis from infected Drosophila melanogaster, and
Mycobacterium tuberculosis DNA spiked into human blood. For each system, we
designed multiple primer sets to explore the effect of various aspects of the primer sets on
reaction efficacy, such as primer melting temperature, binding density on the target
genome, and the evenness of binding sites. These experimental results clarify the relative
importance of each and allow us to describe an effective workflow for using swga.
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3.3. Methods
3.3.1. Program overview
The swga program can be divided into four modules (Fig. 1). The user starts by defining
the target and background sequences using swga init. At this point, a set of sequences
can be supplied that define a priori where primers should not bind, such as a
mitochondrial genome or plasmids (the ‘exclusionary sequences’). The swga count
command then uses DSK (Rizk, Lavenier, & Chikhi, 2013) to identify all nucleotide
sequences in the size range specified by parameters min_size and max_size that exist in
the target genome and do not exist in the exclusionary sequences (if provided). These
primers are used to populate a local SQLite database for later retrieval. The selectivity of
these primers is determined by their frequency in the target genome versus the
background DNA, so swga count saves the frequency that each primer appears in the
target and background as well. Primers that appear extremely rarely in the target and
overly frequently in the background (as defined by user-editable parameters, with
defaults set by swga init), are not saved to help speed up downstream steps. Additionally,
primers that would form internal hairpins or homodimers with themselves are omitted.
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Figure 3-1. An overview of the swga workflow.
An overview of the swga workflow. The program begins by counting all nucleotide sequences of length k
(k-mer) in both the target and background genomes for a given range of k (e.g. 8–12 bp). The k-mers are
then filtered by criteria that include the binding frequencies in the background and target genome, their
melting temperatures, and the likelihood of hairpin or homodimer formation. The best k-mers are then used
to form compatible sets, in which no k-mer would likely form a heteroduplex with any other in the set.
These sets are then evaluated for multiple criteria including binding frequencies and evenness. The results
can be exported into common formats for downstream use and visualization.
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3.3.2. Primer filtering
The command swga filter ranks and filters potential primers by their melting
temperature, selectivity, and evenness of binding in the target genome. First, primers that
bind too sparsely to the target genome (lower than parameter min_fg_bind) or too
frequently to the background (max_bg_bind) are removed. Next, the melting temperature
is approximated using nearest-neighbor thermodynamics (Allawi & SantaLucia, 1997)
with corrections for mono- and divalent cations. Primers with melting temperatures
outside the range defined by min_tm and max_tm are removed. The evenness of binding
then is calculated by finding the Gini index (Gini, 1912) of the distances between each
primer binding site on the target. The Gini index varies between 1 and 0, where 1
represents extremely uneven and 0 represents perfectly even. A primer with a low Gini
index has binding sites that are each separated by similar distances, whereas a primer
with a high Gini index may reflect one where many of the primer binding sites are
clumped together (e.g. on tandem repeat regions). Primers with Gini indices higher than
max_gini are removed. Finally, primers are ranked by the ratio of target binding
frequency to background binding frequency and those primers with the highest ratio are
identified for downstream use (by default, this identifies the top 200 primers, and is
modifiable via the max_primers parameter). The thresholds for each filter are usereditable, and the swga filter command caches results so that it can be quickly re-run to
explore different results.
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3.3.2.1. Primer set evaluation
The swga find_sets command is then used to find sets of compatible primers from the
ones identified in the last step of swga filter. Brute force evaluation of all primer sets is
computationally infeasible: given n primers and a set size of k, the total number of
possible sets is (n choose k). With the default parameters of n=200 and k=2−7, there are
over 2.4×1016 possible sets. Fortunately, not all of these sets are usable for swga. A pair
of primers are incompatible if they form heterodimers (calculated by the number of
consecutive complimentary bases), or if one primer is a subsequence of another. swga
find_sets calculates the pairwise compatibility of all selected primers and stores the
results as a graph. In this graph, primers are vertices and compatible primers are
connected with edges. The problem of finding compatible sets then reduces to a problem
of finding sets of vertices in the graph that are all interconnected (a ‘clique’ in graph
theory). swga also stores the average distance between binding sites on the background as
a ‘weight’ on each vertex. This allows the program to prioritize cliques that have higher
total weights, representing sets of primers that bind infrequently to the background.

To find these cliques, the swga find_sets command uses a modified version of the
program cliquer (Niskanen & Östergård, 2003). The branch-and-bound algorithm in
cliquer is a computationally efficient way of finding cliques in a graph. We have
extended the algorithm to find only cliques that meet certain criteria. By specifying the
desired criteria a priori the algorithm can skip sets that do not meet the requirements and
save computation time. These criteria include the minimum distance between binding
sites in the background (min_bg_bind_dist) and maximum distance between binding sites
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on the target (max_fg_bind_dist). In addition, the algorithm can explore a range of set
sizes (min_size and max_size) in order to find valid sets. By specifying a broad range of
set sizes, the algorithm is able to find sets with a broad range of characteristics
independent of the number of primers.

Primer sets that meet these criteria are further evaluated on metrics including the average
and maximum distance between primer binding sites on the target genome and the Gini
index of all binding sites in the set. These sets and their accompanying metrics are then
saved. Even with the above optimizations, the number of valid sets can be quite large. For
this reason, swga find_sets can be safely stopped after evaluating and storing a sufficient
number of sets. In our usage, we generally stop after 1–5 million sets have been saved.

3.3.2.2. Primer set output and visualization
The saved primer sets can be explored and exported using swga export. This command
allows the user to order the sets by any of the evaluated metrics, export all or some of the
sets of interest to Excel-compatible formats, or export a set to a BedGraph or BedFile
format for visualization in a genome browser (Kent et al., 2002)

3.3.3. Empirical primer set testing
To evaluate swga, we used it to design primer sets for amplification of W. pipientis DNA
against a background of D. melanogaster and of M. tuberculosis against a background of
H. sapiens. We evaluated primer sets on their ability to selectively and evenly amplify the
target genome.
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3.3.3.1. Designing primer sets for W.Pipientis
We created four primer sets for W. pipientis against D. melanogaster, varying each by
melting temperature range, selectivity, and evenness of binding sites on the target
genome. We first initialized swga on the W. pipientis genome with D. melanogaster as
the background, and ran swga count to store all potential primers.
For the first two sets, we used swga filter with the ‘standard’ temperature range
established in Leichty and Brisson (2014), and default in swga, of 15–45°C. This range
we named Tm Low, or TmL. After running swga find_sets and storing 1 million sets, we
used swga export to output the set with the lowest target to background binding distance
ratio, which we called Set TmL/Selective. We then used swga export again to output the
set with the lowest Gini index, which we called Set TmL/Even.

The next two sets were designed with a higher melting temperature range. We re-ran
swga filter with a Tm range of 35–55°C, which we named Tm High, or TmH. As above,
we then re-ran swga find_sets on the new primers and chose the most selective and most
even sets from the results. These are called TmH/Selective and TmH/Even, respectively.
The complete parameter listing is included in Section §3.7.3. The primers belonging to
each set are given in Supp. Table 3-1.

3.3.3.2. Designing primer sets for M. tuberculosis
We created ten primer sets for M. tuberculosis using swga. Our target genome was M.
tuberculosis strain H37Rv (NC_000962.3) and our background was the human genome,
version GRCh38. For this system, we ran swga filter with a temperature range constant
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at 15–45°C, and imposed a maximum per-primer Gini index of 0.6. We stopped swga
find_sets after storing five million sets and exported all of them to CSV format using
swga export. The sets were filtered to only sets with mean distance between target
binding sites <5000 bases. We selected ten sets with the most extreme combinations of
mean target binding distance and evenness (via the metrics fg_dist_mean and
fg_dist_gini, respectively). These sets we named Mtb1 through Mtb10. The distribution
of these sets in the pool is visualized in Supp. Figure 3-1. In addition, we selected from
the original five million the set with the highest Gini index (most uneven) and highest
mean target binding distance as negative comparisons, named MtbUneven and
MtbSparse, respectively. The full parameter listing is included in Section §3.7.3.2. The
primers belonging to each set are given in Supp. Table 3-2.

3.3.4. Selective whole-genome amplification and sequencing
The Wolbachia-specific primer sets were tested on pooled genomic DNA extracted from
10 Wolbachia-infected D. melanogaster (strain Dmel\w118). Pooling was performed to
eliminate inter-fly variability in Wolbachia infection levels, and each primer set was
tested in triplicate using 40 ng of input DNA per reaction, except as noted for additional
tests of the TmL/Even Wolbachia primer set. For consistency with the approach used in
Leichty and Brisson (2014), the pooled genomic extract was digested with NarI (NEB,
New England Biolabs, Inc., Ipswich, MA, USA) at 37°C for 30 minutes, in order to
suppress mitochondrial amplification. This step is likely unnecessary in the general case
because swga includes an option to omit mitochondrial sequences from primer formation.
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Mycobacterium primer sets were tested on purified M. tuberculosis DNA (strain H37Rv,
ATCC 27294D-2), diluted to 1% in human genomic DNA extracted from cultured
CD4+ T cells. Primer sets were tested in triplicate.

Selective whole-genome amplification was performed as previously described
(Sundararaman et al., 2016), with slight modifications. Reactions were performed in a
volume of 50 μL using input DNA, 3.5 mM total of SWGA primers, 1× phi29 buffer
(New England Biolabs), 1 mM dNTPs and 30 units phi29 polymerase (New England
Biolabs). Amplification conditions included a 1 h ramp-down step (35–30°C), followed
by a 16 h amplification step at 30°C. Phi29 was then denatured for 10 min at 65°C.

Amplified samples were purified using AmpureXP beads (Beckman Coulter), prepared
for Illumina sequencing as described in (Kryazhimskiy, Rice, Jerison, & Desai, 2014),
and sequenced on an Illumina MiSeq (150 bp, paired end). We also sequenced the
unamplified pool to establish a baseline for amplification efficiency. Illumina-specific
adapter and primer sequences were removed from the reads using cutadapt (Martin,
2011). In both systems, reads were first aligned to the background (D. melanogaster or
human) using smalt (Ponstingl & Ning, 2010). Unmapped reads were then mapped to the
target genome (W. pipientis or M. tuberculosis, respectively), also using smalt. Analysis
of sequence coverage of the target genome and sequencing rarefaction analyses were
performed using R (R Core Team, 2017). All code used in the analysis and to generate
the figures is available online at https://github.com/eclarke/swga_paper.
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3.4. Results
We used swga to design four primer sets for amplifying Wolbachia against a background
of D. melanogaster, which tested the effect of melting temperature ranges, selectivity,
and evenness. We designed twelve primer sets for amplifying M. tuberculosis against a
background of human DNA with varying primer binding evenness and density on the
target. Ten sets tested were various combinations of high density and evenness. Two, for
comparison, were the most uneven and most sparse. For M. tuberculosis, we compared
amplification using random hexamers (e.g. standard MDA) to the swga-designed primer
sets.

3.4.1. Evaluation of primer sets for W.pipientis
The four primer sets for W. pipientis were designed with two different temperature ranges
(TmL: 15–45°C, TmH: 35–55°C). From the sets identified in each temperature range, we
chose the set with the highest selectivity, defined by the lowest target to background
binding distance ratio (TmL/Selective and TmH/Selective). We also chose the sets with
the most even distribution of binding sites (TmL/Even and TmH/Even). As a control, we
included the primer set from Leichty and Brisson (2014). The composition and metrics
for each of these five sets is shown in Table 3-1.
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Table 3-1. Primer sets for Wolbachia.
Ratio
# Primers
TmL/Selective 0.0544 9
TmL/Evena 0.1050 7
TmH/Even 0.0075 2
TmH/Selective 0.0005 2
Leichty 2014 0.0163 2

Gini
0.654
0.537
0.537
0.66
0.712

Mean target dist
5.33E+03
6.85E+03
1.31E+04
1.21E+04
5.31E+03

Mean bg. dist
9.78E+04
6.53E+04
1.73E+06
2.43E+07
3.25E+05

Characteristics of primer sets chosen for selective whole-genome amplification of Wolbachia from infected
Drosophila DNA. ‘Ratio’ is the ratio of average distance between binding distances in the target and
background. a The set that most effectively amplified Wolbachia.

The pooled genomic DNA contained 4.7% W. pipientis DNA, as determined by
sequencing of the unamplified control. We recovered ∼200 Mbp of sequence for each
amplicon. The proportion of sequencing reads that were derived from W. pipientis was at
least 2.5 times greater in all amplified samples than the sequencing reads from the
unamplified genomic extract (Supp. Figure 3-2). We found that the primer sets with the
higher melting temperatures (TmH/Selective and TmH/Even) yielded more Wolbachia
reads as a total percentage, with some replicates as high as 77.8%. However, these primer
sets failed to reach 10× coverage on even 10% of the W. pipientis genome (Figure 3-2).
This was most likely due to uneven amplification of the target genome, as shown in
Supp. Figure 3-3.
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Figure 3-2. Sequencing effort required to cover Wolbachia genome.
Selective whole genome amplification reduces the sequencing effort necessary to achieve at least ×10
coverage across the W. pipientis genome. Each color represents an individual technical replicate; dashed
lines represent the unamplified control. Lines above the unamplified control represent better sequencing
efficiency in that they yielded greater coverage of the target genome with less sequencing effort.
Sequencing 100 million bases from unamplified genomic DNA extracted from 10 flies resulted in 10-fold
or greater sequencing coverage in only 2.8% of the W. pipientis genome. In contrast, the TmL/Even primer
set resulted in 10-fold or greater coverage of 60–75% of the W. pipientisgenome with similar sequencing
effort. This fraction was increased further to 72–91% when the TmL/Even primer set was used to
amplify W. pipientis from 20 ng (rather than 40 ng) of total fly extract DNA (empirically, using lower total
starting DNA can yield higher relative amplification when using phi29). The TmL/Selective primer set and
the manually chosen set (Leichty & Brisson, 2014) improved W. pipientis sequence coverage relative to the
unamplified sample. However, both of these sets failed to improve sequencing efficiency due an
unevenness of coverage. The high Tm sets enriched only small portions of the genome and thus did not
improve the genome coverage relative to the control.

In contrast, the sets designed with the standard, lower melting temperature range (TmL)
yielded more even coverage across the genome (Supp. Figure 3-3). The TmL/Even
primer set, selected for having the most even distribution of primer sites across the
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Wolbachia genome, gave high, even coverage across the target (Figure 3-3; Supp. Figure
3-3). Moreover, the TmL/Even set reduced the sequencing effort required to achieve 10×
coverage across 90% of the genome by 10-fold relative to the unamplified control (Figure
3-2), extrapolating from the still-rising unamplified control’s rarefaction curve. While the
final two sets—TmL/Selective and the Leichty set—provided more even coverage of the
genome than the TmH sets, they ultimately did not outperform the unamplified control.
The previously-published primer set from Leichty and Brisson (2014) yielded low total
amplification efficiency (12.1–27.7%) and uneven coverage, while the TmL/Selective set
had high amplification efficiency (50–60%) but similarly uneven coverage.

We had originally expected that high numbers of primer binding sites in local regions of
the genome would provide better coverage of that region. This was not seen in any of the
sets tested (Supp. Figure 3-4). In each of the five sets tested, we did not detect a
correlation between the number of primer binding sites and coverage. However, in primer
sets with an overall higher density of binding sites on the target (as measured by a low
average distance between binding sites), we had generally higher coverage across more
of the Wolbachia genome (compare Figure 3-2 and Table 3-1).
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Figure 3-3. Genome coverage by primer sets.
Sequencing coverage of two swga-chosen sets, and the set from Leichty and Brisson (2014), across the W.
pipientis genome. The depth of sequencing coverage per 1 Mb of sequencing effort (1 Mb * coverage
depth/total bp sequenced) is shown for representative replicates of TmH/Even and TmL/Even (red lines)
relative to the unamplified control (black lines). SWGA using the TmL/Even primer set improves depth of
coverage across the majority of the W. pipientis genome by 10- to 100-fold, relative to the unamplified
control. SWGA using the Leichty and Brisson (2014) (top panel) or TmH/Even (middle panel) sets also
improve depth of coverage but over smaller regions of the genome, with the TmH/Even set resulting in high
but localized amplification. Depth of coverage plots for all primer sets and replicates are shown in Supp.
Figure 3-3.

In summary, the primer set with the lowest Gini index and standard melting temperature
(TmL/Even) was the best at selectively and evenly amplifying Wolbachia. While other
sets provided a higher percentage of Wolbachia DNA (Supp. Figure 3-3), the overall
coverage of these sets was low and amplification mostly occurred in specific regions
(Figure 3-3). This suggests that evenness of primer binding sites on the target is a major
factor in the efficacy of the primer set.

3.4.2. Evaluation of primer sets for M. tuberculosis
For M. tuberculosis, we restricted the primer pool to only those with a low Gini index
(<0.6). We let the program identify five million primer sets and then selected only those
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sets whose mean distance between binding sites on the M. tuberculosis genome was <5
kb. From the resulting pool of primer sets, we selected ten sets with the most extreme
combinations of primer set binding evenness and density to test the contributions of each.
These ten will be referred to as our positive tests (Mtb1-10), and the distribution of these
points on the total pool of sets is shown in Supp. Figure 3-1. We also selected the least
selective set and the most uneven set from the five million set pool as negative controls
(MtbSparse and MtbUneven, respectively). The composition and metrics for each of
these 12 sets is shown in Table 3-2.

Table 3-2. Primer sets for M. tuberculosis.
Ratio
# Primers Gini
a
Mtb6 0.0057 7
0.501
a
Mtb9 0.0058 7
0.538
a
Mtb4 0.0062 7
0.512
a
Mtb8 0.0062 7
0.533
Mtb7 0.0066 7
0.499
Mtb2 0.0095 7
0.484
Mtb5 0.0155 6
0.480
Mtb1 0.0171 7
0.476
Mtb3 0.0172 7
0.478
Mtb10 0.0181 7
0.479
MtbUneven 0.0140 2
0.623
MtbSparse 0.0387 3
0.505

Mean target dist.
1.95E+03
1.78E+03
1.88E+03
1.80E+03
2.03E+03
3.29E+03
5.00E+03
4.97E+03
4.99E+03
4.29E+03
1.14E+04
2.60E+04

Mean bg. dist.
3.41E+05
3.05E+05
3.04E+05
2.92E+05
3.09E+05
3.45E+05
3.22E+05
2.90E+05
2.90E+05
2.37E+05
8.10E+05
6.71E+05

Characteristics of primer sets chosen for selective whole-genome amplification of M. tuberculosis from
human DNA, ordered by ratio. ‘Ratio’ indicates the ratio between the average distance between binding
distances in the target and background. Primer sequences are listed in Supp. Table 3-2. a The sets that most
effectively amplified Mycobacterium using SWGA.

The four sets with the lowest mean binding distance (sets Mtb4, Mtb6, Mtb8 and Mtb9)
on the M. tuberculosis genome performed better than the unamplified controls, six other
positive tests, both negative tests and the random hexamers (Figure 3-4 and Table 3-2).
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These sets reached 1× coverage across 38–60% of the M. tuberculosis genome with 200
megabases of sequence, while the remaining six positive tests did not perform better than
the negative controls (Figure 3-4; Supp. Figure 3-5). These four sets yielded higher
coverage across most of the Mycobacterium genome than the unamplified controls, while
the remaining sets either only amplified certain regions or did no better than unamplified
(Supp. Figure 3-6). Deeper sequencing of these four sets’ amplicons showed that the sets
reached 10× coverage over 29–50% of the target by 1.5 Gbp of sequencing effort, with
the unamplified controls only reaching 10× coverage on 2.5% of the target for the same
sequencing effort (Figure 3-5).
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Figure 3-4. Genome coverage using a range of set designs.
Selective amplification of Mycobacterium using swga-designed sets that prioritized primer-level evenness
and set-level binding density and selectivity. Curves indicate the percent of the target covered at 1X depth.
Sets are ordered by the ratio of average distance between primer binding sites on the target to average
binding distance on the background. The coloring indicates individual replicates, and the black dashed line
indicates the unamplified control. The sets with the lowest ratios returned greater coverage of the target
genome compared to unamplified controls than those with higher ratios, as shown by the rarefaction curves
of these sets being higher than the dashed lines.
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Figure 3-5. Deeper sequencing of M. tuberculosis.
Deeper sequencing of four primer sets yields greater coverage of M. tuberculosis genome. The colored
lines indicate individual replicates and the green dashed line is the pooled total. All four sets yield ∼10-fold
increases in efficiency over the unamplified samples (black dashed line). The primer sets reach ×10
coverage on between 28 and 50% of the target genome while the unamplified controls were at < 2.5% ×10
coverage with 1.5 Gbp of sequencing.

For Mycobacterium, we found that sets with smaller distances between primer binding
sites on the target genome outperformed those optimized for lower Gini index. Nine out
of the ten positive test Mycobacterium sets, including the four best sets, had lower Gini
indices than the sets for Wolbachia. This suggests that after a certain threshold the Gini
index becomes secondary to the primer binding site density. Therefore, pre-selecting
primers with a low Gini index during swga filter and then choosing sets with high
binding density in swga export allows the optimization of both attributes, and should
yield effective primer sets.
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3.5. Discussion
Selective whole-genome amplification provides a way to preferentially amplify a target
genome from a complex background. However, implementation of the SWGA method
has been limited due to the difficulties in designing an effective set of primers.
Assembling a primer set where all of the primers are compatible with each other,
selective for the target genome, and rare in the background is a problem with many
degrees of freedom. The swga program addresses this difficulty by automatically
identifying and evaluating primer sets by specified criteria, allowing the user to select
only those sets most likely to succeed in selective amplification of the target.

We used swga to design primer sets for W. pipientis and M. tuberculosis that selectively
amplified each in the presence of their host’s genome. These sets had varying binding
evenness and selectivity for the target genome, allowing us to compare these attributes to
the performance of each set. In addition, we demonstrated potential clinical utility of the
swga program by amplifying DNA from the M. tuberculosis pathogen spiked into human
blood. While in these experiments we used target/background pairs with clearly defined
genomes, there is no reason the background cannot be a heterogenous mixture of DNA,
such as stool or soil. In this case, the background could be approximated by wholegenome shotgun sequencing of the mixture, and subtracting any reads belonging to the
target, if present.

Based on these results, it appears that primer binding evenness (as measured by the Gini
index), primer set binding selectivity, and the density of binding sites on the target
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genome each play an important role in the set’s efficacy. In the W. pipientis study, we
established that the temperature range of 15–45°C for the primers and prioritizing
evenness of binding led to more even amplification of the target genome. In addition, the
swga-designed sets performed better at selectively amplifying the target than the handdesigned set in (Leichty & Brisson, 2014). In fact, the Leichty primer set was not
generated by swga because the maximum distance between primer sites on the Wolbachia
genome was greater than the specified cutoff. In M. tuberculosis, by starting with a pool
of primers that bind relatively evenly to the target, we constrained the range of set
binding evenness by removing primers that cluster on repeat regions. After controlling
the range of binding evenness at the primer level, the sets with the highest target binding
density (i.e. lowest mean distance between binding sites) achieved highest coverage,
suggesting that further refinements of the sets for evenness is not necessary. These sets
consequently had the lowest ratio of target to background average binding distances. This
ratio, as a more complete representation of the set’s selectivity than just the binding
density on the target, had a strongly inverse correlation with the amount of the genome
covered after sequencing (Figure 3-6). Because both attributes are closely related, it is
difficult to disentangle the effects of binding density from the effects of a low ratio, and it
may be that either or both of these attributes contribute to the success of these primer
sets. Furthermore, some sets had relatively similar ratios (e.g. Mtb7 versus Mtb8), but
Mtb8 yielded greater genome coverage. This indicates that there are likely other set
attributes not considered here that also contribute to set efficacy. To compensate for this,
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we suggest selecting five to ten sets with low ratios to test experimentally, and then
selecting the best-performing of those sets.

Figure 3-6. Coverage is related to set selectivity.
The percentage of the Mycobacterium genome covered by each set at ×1 coverage after 50 Mbp of
sequencing is inversely correlated to the set’s target to background binding distance ratio (e.g. selectivity).
The smoothed line of best fit (LOESS) is shown by the dotted line. The points and whiskers represent the
median and standard deviation of the technical replicates. Positive tests are in blue, while negative controls
are in orange. The random hexamers did not have a definable ratio and are not displayed.

The swga program does not consider a specific number of primers for each set. Instead,
swga considers primer sets of different sizes, and reports suggested sets. By exploring a
range of sizes, the swga program allows the user to find sets with desirable attributes
without having to guess what the ideal set size will be in advance.

SWGA is best suited to large scale population genomics studies and may not be cost
effective in some smaller studies. Developing the SWGA primer set requires up-front
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costs that need to be recovered in later applications for the method to be cost effective. A
detailed cost-benefit analysis over multiple applications is presented in Section §3.7.4.
SWGA is most useful when large numbers of samples are to be sequenced, when the
target genome is rare in the unamplified sample, and when higher sequencing coverage of
the target genome is desired.

Our experiments so far suggest a general workflow that can be used to design primer sets
for other systems. In particular, we recommend the following guidelines:
•

During swga filter, set the max_gini parameter as low as possible while still yielding
200 or more primers.

•

For swga find_sets, set the max_sets to 1–5 million to explore a wide range of set
attributes.

•

Use swga export to export the sets ordered by the distance between binding sites on
the target (attribute fg_mean_dist).

•

Pick the five to ten sets with lowest fg_mean_dist to test experimentally. Barcode
each amplicon separately, then pool and sequence with low depth to assess
performance. Once a high-performing set is identified, sequence that amplicon more
deeply. This set is now usable in any samples that have similar target/background
combinations.

We expect best practices to evolve as SWGA is used more frequently. To facilitate this,
we have set up a web page on the project’s source repository and a user mailing list. A
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tutorial on the program’s operation and more extensive documentation on each parameter
and module is available on the web page as well.

3.6. Acknowledgements
We thank Michael Parisi for his generous donation of Wolbachia-infected Drosophila
strains, as well as Alex Berry and other early swga users for their feedback.
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3.7. Supplemental Material
3.7.1. Supplemental Figures

Supp. Figure 3-1.
The sets identified for Mycobacterium tuberculosis with a mean binding distance on the target less than 5kb
are shown as a hexplot, where the color intensity represents the number of sets within that range of binding
density (x-axis) and evenness (y-axis). We used the ‘chull’ function in R to detect the inflection points of
this distribution. These points (red dots) were the sets that were used for selective amplification. They
represent various extreme combinations of primer binding evenness and density. Where there were multiple
points close together, we picked one at random.
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Supp. Figure 3-2.
Selective whole-genome amplification increases the proportion of sequencing reads that map to the target
genome. Direct sequencing of total DNA of 10 flies (column labelled ø) resulted in more than 93% of reads
mapping to Drosophila while only 4.7% mapped to Wolbachia. By contrast, at least 15% of the reads
mapped to Wolbachia after select whole genome amplification with the worst performing primer set. All
primer sets identified by the swga program performed substantially better than primer sets chosen manually
(Leichty, 2014). Results from each of three replicate SWGA reactions (using 40 ng total DNA per reaction)
per primer set are shown. The TmL/Even primer set was also run in triplicate with 20 ng total DNA per
reaction. Results were more similar for replicates within a set than between sets, indicating that SWGA
performs consistently when using the same primer set.
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Supp. Figure 3-3.
The depth of sequencing per 1Gb of sequencing effort (1 Gb * coverage depth / total bp sequenced) is
shown for all replicates of all primer sets chosen for Wolbachia against Drosophila. Colored lines indicate
technical replicates, while the black line indicates the unamplified control. The TmL/Even set was resequenced with 20ng of total fly extract DNA in addition to the 40ng used for the other sets. The
TmL/Even amplicons consistently achieved higher coverage of the Wolbachia genome than the
unamplified control.
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Supp. Figure 3-4.
Variation in the local density of primer binding sites does not account for variation in select whole
amplification across the Wolbachia genome. The normalized mean sequencing coverage (1 Mb * coverage
depth / total bp sequenced) across 5 kb windows after amplification is shown relative to the number of
binding sites within a 20 kb window. Smoothed (LOESS) best fit lines (blue lines) are plotted for each
technical replicate. Within each primer set, normalized mean coverage did not correlate with the number of
binding sites in a 20 kb window. However, coverage did vary between primer sets and was generally higher
for primer sets with a higher number of primer binding sites (Table 1).
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Supp. Figure 3-5.
10x coverage of the Mycobacterium genome was limited without additional sequencing effort. Colored
lines indicate technical replicates, while black dashed lines indicate the unamplified control.
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Supp. Figure 3-6.
The depth of sequencing per 1Gb of sequencing effort (1 Gb * coverage depth / total bp sequenced) is
shown for all replicates of all primer sets chosen for Mycobacterium against the human genome. The first
four sets yielded higher coverage of the Mtb genome than the unamplified control, as indicated by each the
colored line for each replicate being higher than the unamplified control (black line). For each set, a density
histogram of the ratio between the average set coverage and the unamplified control is shown on the right.
Peaks to the right of the dashed line (indicating a ratio greater than 1) represent overall enrichment.
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3.7.2. Supplemental Tables
Supp. Table 3-1. Wolbachia primer sets
ID

Ratio

Size

Gini

Max target dist

Mean target dist.

TmL/Selective

0.0544

9

0.65

3.11E+04

5.33E+03

TmL/Even

0.1050

7

0.54

3.47E+04

6.85E+03

TmH/Even

0.0075

2

0.54

1.13E+05

1.31E+04

TmH/Selective
Leichty and Brisson
2014

0.0005

2

0.66

1.28E+05

1.21E+04

0.0163

2

0.71

1.13E+05

5.31E+03

ID

Target
dist (sd)

Mean bg.
dist

TmL/Selective

7.00E+03

9.78E+04

TmL/Even

7.00E+03

6.53E+04

Primers
AACATAGATC,AAGAGATACC, AATGTTCGTA,
ACGTGTTAG, AGAAATTTACTA,
ATCTAGAGAT, ATCTATGTTAAG,
TACGTCATAC, TATGCAAGAA
AATGTTCGTA, ATAAGCTGAA, TAAAGACATA,
TACGTCATAC, TATGCAAGAA, TGAGATACC,
TTTCTGGATC

TmH/Even

1.55E+04

1.73E+06

CACTGGAATCC, CGCTACTTGTTA

TmH/Selective
Leichty and Brisson
2014

1.80E+04

2.43E+07

CTACGTGTTAGC, CTACTTGTTAGC

1.01E+04

3.25E+05

ATCCAAGTAG, CGGTATCTC
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Supp. Table 3-2. Mycobacterium primer sets.
Name

ID

Max target dist

Mean target dist.

Mtb1

1130935

0.0171

7

0.476

3.27E+04

4.97E+03

Mtb2

1236643

0.0095

7

0.484

2.75E+04

3.29E+03

Mtb3

1482488

0.0172

7

0.478

3.77E+04

4.99E+03

Mtb4

1558358

0.0062

7

0.512

1.49E+04

1.88E+03

Mtb5

1951361

0.0155

6

0.480

3.44E+04

5.00E+03

Mtb6

4690256

0.0057

7

0.501

1.50E+04

1.95E+03

Mtb7

4715948

0.0066

7

0.499

1.39E+04

2.03E+03

Mtb8

5192056

0.0062

7

0.533

1.87E+04

1.80E+03

Mtb9

5194179

0.0058

7

0.538

1.87E+04

1.78E+03

Mtb10

5699436

0.0181

7

0.479

3.12E+04

4.29E+03

MtbUneven

70336

0.0140

2

0.623

9.21E+04

1.14E+04

MtbSparse

146196

0.0387

3

0.505

1.00E+05

2.60E+04

Target
Dist (sd)

Mean bg.
dist

Name

Ratio

Size

Gini

Mtb1

4.56E+03

2.90E+05

Mtb2

3.12E+03

3.45E+05

Mtb3

4.69E+03

2.90E+05

Mtb4

1.92E+03

3.04E+05

Mtb5

4.71E+03

3.22E+05

Mtb6

1.95E+03

3.41E+05

Mtb7

1.99E+03

3.09E+05

Mtb8

1.96E+03

2.92E+05

Mtb9

1.96E+03

3.05E+05

Mtb10

4.09E+03

2.37E+05

Primers
ACGATCA*A*C,CCGATAT*G*G,CGCGAA*T*A,CGCG
AT*T*A,CGTCGT*A*G,CGTCGT*A*T,TAGTCGA*T*G
ATTCGT*C*G,CGCGAA*T*A,CGGTAT*C*G,CGTCGT*
A*A,CGTCGT*A*T,GATTGTC*G*A,TACGAA*C*G
ATCGGAT*T*C,CGATAC*G*T,CGCGAT*A*A,CTACGA
*C*G,CTCGATA*C*C,GATCGAC*T*C,TCGATCA*A*C
ATCGACA*A*C,CGAATC*C*G,CGTTAC*G*G,CTACG
A*C*G,GACGAT*C*G,GATCGAC*T*C,TCGACG*A*A
ATATCGG*T*G,CCGAAT*C*G,CGGTTA*C*G,GACGA
CT*A*C,GATGATC*G*A,TGGATAT*C*G
CCGAAT*C*G,CGCGAA*T*A,CGCTAT*C*G,CGGTAT*
C*G,CGGTTA*C*G,CGTCTA*C*G,TCGACG*A*A
ATCGACA*A*G,CCGAAT*C*G,CGCGAA*T*A,CGCTA
T*C*G,CGGTAT*C*G,CGTCTA*C*G,TCGACG*A*A
ACGATCA*A*C,CGAATC*C*G,CGACGA*A*A,CGACG
A*T*A,CGATAC*C*G,TACGAC*G*A,TCGACG*A*A
CGAATC*C*G,CGACGA*A*A,CGACGA*T*A,CGATAA
*C*G,CGATAC*C*G,TACGAC*G*A,TCGACG*A*A
CGAAAC*G*A,CGATATC*C*A,CGATTC*G*G,CGGTA
TT*G*A,CGTAGT*C*G,CGTTAC*G*T,TGTAGTC*G*A

MtbUneven

1.45E+04

8.10E+05

CGATATT*G*C,CGTTAC*C*G

MtbSparse

2.48E+04

6.71E+05

CGTTCG*T*A,TGATATC*G*C,TTCGACT*A*C

99

3.7.3. Supplemental Data
3.7.3.1. Swga settings for Wolbachia pipientis against Drosophila melanogaster
[count]
min_size = 5
max_size = 12
min_fg_bind = 20
max_bg_bind = 10000
max_dimer_bp = 4
exclude_threshold = 1
[summary]
bg_length = 145523498
fg_length = 1285894
[filter]
max_primers
bg_length =
fg_length =
min_fg_bind
max_bg_bind
min_tm = 15
max_tm = 45

= 200
145523498
1285894
= 41
= 474

[find_sets]
min_size = 2
max_size = 12
max_dimer_bp = 4
min_bg_bind_dist = 30000
bg_genome_len = 145523498
max_fg_bind_dist = 36000
max_sets = 1
workers = 3
[score]
bg_genome_len = 145523498
score_expression = (fg_dist_mean * fg_dist_gini) / (bg_dist_mean)
[export]
window_size = 10000
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3.7.3.2. Swga settings for Mycobacterium tuberculosis against Homo sapiens.
[count]
min_size = 5
max_size = 12
min_fg_bind = 44
max_bg_bind = 21770
max_dimer_bp = 3
exclude_threshold = 1
[export]
window_size = 10000
[filter]
max_primers = 200
min_fg_bind = 50
max_bg_bind = 21770
min_tm = 15
max_tm = 45
max_gini = 0.6
[find_sets]
min_size = 2
max_size = 7
max_dimer_bp = 3
min_bg_bind_dist = 60000
max_fg_bind_dist = 100000
max_sets = -1
workers = 4
score_expression = (fg_dist_mean * fg_dist_gini) / (bg_dist_mean)
[score]
score_expression = (fg_dist_mean * fg_dist_gini) / (bg_dist_mean)

3.7.3.3. Code used in this project
For code used in analysis and figures, please refer to
https://github.com/eclarke/swga_paper

3.7.4. Cost analysis for SWGA
The SWGA method improves the efficiency of genomic sequencing when targeting the
genome of a specific organism in the presence of contaminating DNA. However,
implementing SWGA itself incurs costs, and so not all applications will benefit from its
use. In particular, SWGA is generally more cost effective studies that require sequencing
a large fraction of the target genome from multiple samples. For experiments
necessitating new primer design, as described in this study, either the depth of sequencing
coverage or number of samples must be large enough to offset initial cost of purchasing
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and testing primer sets. For these reasons, SWGA, using newly designed primer sets, is
not necessarily cost effective for applications with very small target genomes, low
coverage depth , or small numbers of samples.
Here we present a cost analysis, including the cost of de novo primer set design and
testing. To highlight the areas where SWGA is most cost effective, we have performed
this analysis across range of sequencing depths for three target organisms:
Mycobacterium tuberculosis in humans, Plasmodium vivax in humans, and Wolbachia
pipientis in fruit flies. The cost of implementing and performing SWGA is compared
directly to achieving the same depth and coverage of sequencing by direct sequencing of
the sample without SWGA amplification.
For each target, we compare the cost of SWGA sequencing for a given number of
samples, including primer set design and testing, to that of sequencing directly from the
starting DNA mixture. We calculate the cost of sequencing samples at 1X and 10X
coverage and with the goal of covering 50%, 75%, and 80% of the target genome, thus
illustrating how the cost effectiveness of SWGA varies with depth and breadth of
sequencing.
The following is a breakdown of the costs associated with sequencing and the SWGA
process. All costs are in US dollars, and reagent prices are accurate as of the time of
writing (Feb 2017).
Supp. Table 3-3. One-time costs associated with SWGA.
Step
Unit
Cost
Primer design
Computation time*
$5.88
Primer testing
Miseq (reagents + sequencing)
$1,500.00
Computation time measured as the cost of running swga on the Penn High Performance Computing cluster
on one node for one week at $0.035/hr/node.
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Supp. Table 3-4. Per-sample costs associated with SWGA.
Step
Unit
Cost/sample
Primer Set (average for 10 primers)
Primer oligos
$0.02
SWGA Reaction
Phi29 + Buffer $5.70
SWGA Reaction
DNTPs
$0.41
Sequencing (Nextera - Hiseq)
Kit reagents
$65.00
Cost per base on an Illumina Hiseq using Nextera: $0.000000094.
Total cost is $71.13/sample. Costs per sample were estimated from the cost of and number of uses yielded
by the reagent (for specific reagent catalog numbers, see the main text).

To calculate the cost of sequencing some number of samples 𝑛 with SWGA, we added
the fixed costs (𝐶𝑓 ) and multiplied the variable costs 𝐶𝑣 by the number of samples. We
then empirically determined the number of bases required to achieve the required depth
of coverage (𝑁𝑏𝑝 , see Table 2 at end of document). This was multiplied by the above cost
per base (𝐶𝑏𝑝 )and the number of samples:
Cost SWGA (𝑛) = 𝐶𝑓 + (𝐶𝑣 × 𝑛) + (𝑁𝑏𝑝 × 𝐶𝑏𝑝 × 𝑛)
The cost of directly sequencing a sample (without SWGA) is the cost of the sequencing
reagents (𝐶𝑟 ) and the sequencing itself:
Cost Unamplified (𝑛) = (𝐶𝑟 × 𝑛) + (𝑁𝑏𝑝 × 𝐶𝑏𝑝 × 𝑛)
In each plot, the intersection point between the two lines (SWGA vs unamplified)
represents the point at which the SWGA method becomes more cost efficient. This is
heavily influenced by the relative efficiency gains yielded by SWGA, which itself is a
function of the target and host genomes. For some applications, like sequencing W.
pipientis at low coverage depth and breadth, SWGA is not cheaper than conventional
sequencing.
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Ex. 1: M. tuberculosis at 10X depth o ver 80% of the genome

Ex. 2: M. tuberculosis at 10X depth o ver 75% of the genome

$60,000

$40,000

SWGA

Cost

Cost

$40,000

SWGA

Unamplified

Unamplified
$20,000

$20,000

$0

$0
0

25

50

75

100

0

Number of samples

25

50

75

100

Number of samples

Ex. 3: M. tuberculosis at 10X depth o ver 50% of the genome

Ex. 4: M. tuberculosis at 1X depth o ver 80% of the genome

$40,000
$10,000

SWGA
$20,000

Cost

Cost

$30,000

Unamplified

SWGA
Unamplified

$5,000

$10,000

$0

$0
0

25

50

75

0

100

Number of samples

25

50

75

100

Number of samples
Ex. 6: M. tuberculosis at 1X depth o ver 50% of the genome

Ex. 5: M. tuberculosis at 1X depth o ver 75% of the genome
$12,500

$10,000

$7,500

SWGA

Cost

Cost

$7,500
$5,000

SWGA

Unamplified

$5,000

Unamplified
$2,500

$2,500

$0

$0
0

25

50

75

0

100

25

50

75

100

Number of samples

Number of samples
Ex. 7: P. vivax at 10X depth over 80% of the genome

Ex. 8: P. vivax at 10X depth over 75% of the genome

$400,000

$300,000

SWGA

$200,000

Cost

Cost

$300,000

$200,000

SWGA

Unamplified
$100,000

$100,000

$0

$0
0

25

50

75

Number of samples
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Unamplified

100

0

25

50

75

Number of samples

100

Ex. 9: P. vivax at 10X depth over 50% of the genome

Ex. 10: P. vivax at 1X depth over 80% of the genome

$300,000

$40,000

SWGA

Cost

Cost

$200,000
SWGA

Unamplified

Unamplified
$20,000

$100,000

$0

$0
0

25

50

75

100

0

Number of samples

25

50

75

100

Number of samples

Ex. 11: P. vivax at 1X depth over 75% of the genome

Ex. 12: P. vivax at 1X depth over 50% of the genome

$50,000

$40,000
$20,000

SWGA

Cost

Cost

$30,000
SWGA

Unamplified

$20,000

Unamplified
$10,000

$10,000

$0

$0
0

25

50

75

0

100

Number of samples

25

50

75

100

Number of samples

Ex. 13: W. pipientis at 10X depth o ver 80% of the genome

Ex. 14: W. pipientis at 10X depth o ver 75% of the genome
$10,000

$9,000

$6,000

SWGA

Cost

Cost

$7,500

SWGA

$5,000

Unamplified
$3,000

$2,500

$0

$0
0

25

50

75

Number of samples

105

Unamplified

100

0

25

50

75

Number of samples

100

Ex. 15: W. pipientis at 10X depth o ver 50% of the genome

Ex. 16: W. pipientis at 1X depth o ver 80% of the genome

$7,500

$5,000

SWGA

Cost

Cost

$7,500

$5,000
SWGA

Unamplified

Unamplified
$2,500

$2,500

$0

$0
0

25

50

75

100

0

Number of samples

50

75

100

Number of samples

Ex. 17: W. pipientis at 1X depth o ver 75% of the genome

Ex. 18: W. pipientis at 1X depth o ver 50% of the genome

$7,500

$5,000
SWGA

Cost

$7,500

Cost

25

$5,000
SWGA

Unamplified
$2,500

$2,500

$0

$0
0

25

50

75

Number of samples
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Unamplified

100

0

25

50

75

Number of samples

100

Supp. Table 3-5. Sequencing required to achieve desired coverage.
Example
Organism
Depth Coverage
SWGA (bp)
1
M. tuberculosis
10
80
3,091,559,998
2
M. tuberculosis
10
75
2,520,410,974
3
M. tuberculosis
10
50
1,223,345,194
4
M. tuberculosis
1
80
303,869,124
5
M. tuberculosis
1
75
238,173,500
6
M. tuberculosis
1
50
85,299,735
7
P. vivax
10
80
4,129,854,209
8
P. vivax
10
75
2,780,236,529
9
P. vivax
10
50
837,785,449
10
P. vivax
1
80
590,545,217
11
P. vivax
1
75
289,985,276
12
P. vivax
1
50
64,803,452
13
W. pipientis
10
80
71,621,179
14
W. pipientis
10
75
62,712,293
15
W. pipientis
10
50
36,527,254
16
W. pipientis
1
80
7,234,721
17
W. pipientis
1
75
5,946,277
18
W. pipientis
1
50
2,451,818

Unamplified (bp)
5,527,190,382
5,262,496,048
4,267,942,796
710,912,333
612,325,622
307,065,400
40,750,765,958
38,803,668,507
31,291,283,092
5,210,647,250
4,493,713,988
2,249,610,375
441,055,975
390,478,303
256,900,749
50,185,804
42,309,224
19,419,362

3.7.4.1. Conclusions
As shown in Examples 1-3 and 7-12, the cost effectiveness of SWGA is more significant
when pursuing higher coverage depth across the target genome. In M. tuberculosis,
SWGA becomes more cost effective when considering sequencing more than 8 samples.
In P. vivax SWGA is nearly always more cost effective, representative of the variable
effect the target and host genomes can play on the final efficiency gains.
For low-depth sequencing, and for small genomes such as W. pipientis, the benefit is only
realized at higher numbers of samples. Low-depth sequencing of M. tuberculosis is only
more cost-effective with SWGA when more than 65 samples are being sequenced (Ex 46). Again indicative of the variable influence of the target genome size, however, lowdepth coverage of P. vivax is more cost-effective with SWGA by only 5 or so samples.
As a contrast, it is unlikely that SWGA would be cost-effective at all for low-depth
sequencing of W. pipientis given that the lines in Examples 16-18 will only converge
after a very large (>10,000) number of samples. Importantly, these graphs include the
cost of designing and testing new SWGA primers. In situations where primer sets already
exist, SWGA would become cost-effective at even lower numbers of samples.
107

These graphs show that for a variety of target/host genomes, SWGA's benefits are
greatest when 1) large numbers of samples are studied, 2) when high depths of coverage
are needed, and 3) a large proportion of the genome should be covered.
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Chapter 4. T cell dynamics and response of the microbiota
after SCID-X1 gene therapy
This chapter is based upon work by Erik Clarke1, Frances Male, Andrew
Connell1, Nadia Kadry1, Arwa Abbas1, Young Hwang1, John Everett1, Casey
Hofstaedter, Judith Kelsen, Marina Cavazzana, Emmanuelle Six, Alain Fischer,
Luigi Notarangelo, Salima Hacein-Bey Abina, Don Kohn, David Williams, SungYun Pai, and Frederic D. Bushman1.
1. Dept. of Microbiology, University of Pennsylvania School of
Medicine

4.1. Abstract
Mutation of the IL2RG gene results in a severe combined immune deficiency (SCID-X1)
that has been treated successfully with hematopoietic stem cell (HSC) gene therapy.
SCID-X1 gene therapy results in reconstitution of the previously lacking T-cell
compartment, allowing analysis of the roles of T-cells in humans by comparing before
and after gene correction. Here we interrogate T-cell reconstitution using four forms of
high content analysis. 1) Estimation of the numbers of transduced progenitor cells by
monitoring unique positions of integration of the therapeutic gene transfer vector. 2)
Estimation of T-cell population structure by sequencing of the TCR-beta VDJrecombination products. 3) Metagenomic analysis of microbial populations in
oropharyngyl, nasopharyngal and gut samples. 4) Metagenomic analysis of viral
populations in gut samples. Comparison of progenitor and T-cell populations allows
estimation of a minimum number of cell divisions needed to generate the observed
populations. Analysis of microbial populations shows the effects of immune
reconstitution, including normalization of gut microbiota and clearance of viral
infections. Metagenomic analysis revealed a notable enrichment of genes for antibiotic
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resistance in gene-corrected subjects relative to healthy controls. These data highlight the
novel analytical avenues made possible by successful SCID-X1 gene therapy.

4.2. Introduction
Several primary immunodeficiencies have now been treated successfully by genecorrection of hematopoetic stem cells (HSC) with integrating vectors (Aiuti et al., 2013;
Aiuti et al., 2007; Aiuti et al., 2002; Biffi et al., 2013; Marina Cavazzana-Calvo, AndreSchmutz, & Fischer, 2013; Gaspar et al., 2011; Gaspar et al., 2004; Hacein-Bey-Abina et
al., 2010; Hacein-Bey-Abina et al., 2002). This work has benefited many patients, and in
addition provides a unique window on immune mechanisms. In SCID-X1, the first
primary immunodeficiency treated successfully by gene transfer, patients harbor
mutations in the IL2RG gene, which encodes the common gamma chain, a component of
several cytokine receptors important in T and NK-cell growth and development(Kovanen
& Leonard, 2004; Noguchi et al., 1993; Puck et al., 1993). Patients typically lack these
cells before correction(Kennedy et al., 2000; Lodolce et al., 1998; Puel, Ziegler, Buckley,
& Leonard, 1998), but afterwards show robust T reconstitution and transient NK-cell
reconstitution, accompanied by restoration of considerable immune function (Gaspar et
al., 2011; Gaspar et al., 2004; Hacein-Bey-Abina et al., 2010; Hacein-Bey-Abina et al.,
2002). Gene correction thus provides a unique opportunity to study the onset of T cell
function in previously deficient human subjects.

In the first gene therapy trial to treat SCID-X1, early designs of gammaretroviral vectors
were used (Gaspar et al., 2011; Gaspar et al., 2004; Hacein-Bey-Abina et al., 2010;
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Hacein-Bey-Abina et al., 2002), which were the only vector type available at the time.
These vectors contain strong enhancers derived from the starting retroviral backbone.
The enhancers supported efficient expression of the corrective IL2RG gene and allowed
successful gene correction. However, subsequent experience implicated these vectors in
insertional mutagenesis, in which vector signals activated transcription of host protooncogenes, in some cases associated with severe adverse events(Hacein-Bey-Abina, von
Kalle, Schmidt, Le Deist, et al., 2003; Howe et al., 2008).

A second trial was carried out to treat SCID-X1 using an improved vector in which the
strong enhancer sequences were deleted (Hacein-Bey-Abina et al., 2014), and a more
specific promoter was used to express the therapeutic IL2RG gene copy. T-cell numbers
after correction were indistinguishable in the first and second trials. So far, no severe
adverse events have been linked to insertional activation in the second trial.

In this study, we used multiple high throughput sequence-based methods to analyze
samples from the SCID-X1 trials, with the goal of probing immune mechanisms and the
resulting effects on microbial communities. To assess the number and distributions of
gene-corrected precursor cells producing T-cells, deep sequencing of sites of vector
integration was used (C. Berry, Hannenhalli, Leipzig, & Bushman, 2006; C. C. Berry et
al., 2012; C. C. Berry et al., 2017; Hacein-Bey-Abina et al., 2014; Hacein-Bey-Abina,
von Kalle, Schmidt, Le Deist, et al., 2003; Hacein-Bey-Abina, Von Kalle, Schmidt,
McCormack, et al., 2003; Howe et al., 2008; Mitchell et al., 2004; Schroder et al., 2002;
Sherman et al., 2017; G. P. Wang et al., 2010; G. P. Wang et al., 2007), where each
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unique integration site marked a distinct T-cell progenitor. T-cell development could be
followed at a later step by using DNA sequencing to track rearrangements of gene
segments encoding the T-cell receptor-beta CDR3 region (Boyd et al., 2009;
Campregher, Srivastava, Deeg, Robins, & Warren, 2010; H. S. Robins et al., 2009; H. S.
Robins et al., 2010; Weinstein, Jiang, White, Fisher, & Quake, 2009). Immune cells
contribute to control of the resident microbiota, so the consequences of T-cell
reconstitution were assessed by deep sequencing of oral, fecal and nares samples to
characterize the full microbiota using shotgun metagenomics. In a separate analysis,
samples were enriched biochemically for viral particles, RNA and DNA extracted, and
then the viral content monitored in fecal samples.

The data support a wealth of new inferences on T-cell growth and immune activity after
reconstitution. For example, a minimum estimate for the numbers of cell divisions
between progenitor cells and mature T-cells was developed by comparing population
sizes from integration site and TCR sequence data. In the microbiome data,
normalization of microbial communities was documented following successful treatment
in several subjects. Viral infections, several not detected clinically, could be shown to be
widespread but often cleared with immune reconstitution. TCR diversity could be
compared for selected samples from the SCID1 and SCID2 trails, providing information
on the durability of reconstitution and effects of adverse events on TCR diversity. Thus
these data begin to outline the utility of “multi-omics” analysis of gene correction in
primary immunodeficiency.
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4.3. Results
4.3.1. Experimental strategy
Our comparative analysis of gene-corrected progenitors and daughter T cells focused on
four patients from the SCID-2 trail (Hacein-Bey-Abina et al., 2014 ) and three patients
from the SCID-1 trial (Hacein-Bey-Abina et al., 2010) for whom samples were available
Figure 4-1. Patient characteristics are summarized in Supp. Table 4-1. Additional
subjects were studied for which we did not have T cell samples, but did have peripheral
blood mononuclear cell samples (PBMC, Supp. Figure 2-1). Adverse events took place in
the SCID-1 trial involving subjects F107 and F110 at times 68 months and 33 months
after infusion (Hacein-Bey-Abina et al., 2010; Hacein-Bey-Abina et al., 2014; G. P.
Wang et al., 2010). The time points analyzed here are well after these adverse events,
allowing assessment of the effects of leukemia and chemotherapy on progenitor cell and
T cell populations. One subject in the SCID2 trial, B205, was transplanted twice without
achieving clinical reconstitution. Samples from the two unsuccessful treatments are
designated B205 and B205b.

Vector integration sites and the T cell repertoire were monitored through regular perprotocol blood draws, followed by isolation of CD3+ populations. Sorted cells were
subject to DNA extraction and then amplification of either integration sites (mostly
previously reported in (Hacein-Bey-Abina et al., 2010; Hacein-Bey-Abina et al., 2014; G.
P. Wang et al., 2010); Supplementary Table X) or mature TCR beta loci (Supp. Table
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4-3; data new here), followed by sequencing. Vector integration sites mark progenitor
cells capable of delivering mature T-cells to the periphery. Rearranged TCR beta loci
mark mature T-cells present in blood. Time points from the integration site analysis were
chosen to match those used in the TCR analysis—characterization of additional time
points for integration site distributions in SCID-X1 gene therapy can be found in (M.
Cavazzana-Calvo et al., 2000; Hacein-Bey-Abina et al., 2010; Hacein-Bey-Abina et al.,
2014; Howe et al., 2008; Thrasher et al., 2006; G. P. Wang et al., 2010; G. P. Wang et al.,
2008).

Microbiome samples were available for six SCID-2 patients (B201, B203, B204, B205,
B207, and F201). Oral, nasal, and gut microbiota were sampled via collection of
oropharyngeal swabs, nasopharyngeal swabs, and stool samples. Sampling times ranged
from 4 to 181 months post infusion of corrected cells. Sample acquisition was at times
limited by clinical and practical considerations.

As controls, we analyzed TCR-beta sequences from CD3+ cells from five healthy
children and three healthy adults. Healthy subject demographics are in Supp. Table 4-1.
Cross-sectional microbiome samples were collected from the same subjects and analyzed
as for the SCID gene-corrected samples.
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Figure 4-1.
Sampling schedule for eight SCID-X1 gene-corrected subjects studied for integration site distributions and
TCRB CDR3 sequence composition. A) Times of sample acquisition after cell infusion. B) Population
sizes of inferred progenitor cells deduced from marking with unique sites of vector integration. Integration
site data is in Supplementary Table X, and summaries of genes near sites of vector integration are in
Supplementary Figure 2. The x-axis shows the time since cell infusion. The y-axis shows the population
size reconstructed using Chao1 from the numbers of unique integration sites and replicate sampling.
Samples are named for the site of gene correction (B indicates Boston, F indicates France; the next digit
indicates the trail 1=SCID1, 2=SCID2, and the next two digits indicate the patient number within that trial).
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4.3.2. Integration site analysis
To characterize progenitor cells delivering T-cells to the periphery, we determined the
sites of vector integration in patient chromosomes (31 total samples). Because of the
large size of the human genome, each integration site uniquely marks the descendants of
a single gene-corrected progenitor. Summaries of genes near integration sites in the most
expanded clones at each time point are in Supp. Figure 4-2. The numbers of integration
sites detected in purified T cell samples ranged widely, from as few as 62 to as many as
2009. Reconstruction of population sizes using the Chao1 estimator suggested minimal
sizes of 144 to 6018 active progenitors.

For the SCID2 subjects, we found that the estimated total number of vector integration
sites was relatively constant over the time intervals analyzed (Figure 4-1B), in the range
of ~1000 predominant clones yielding circulating cells (Supp. Table 4-2). Numbers
varied by subject, with subject B203 showing consistently higher levels, while B205, a
case of unsuccessful reconstitution, showing consistently lower levels.

For the SCID1 subjects, numbers of unique sites identified varied from 263 to 682;
reconstructed minimal population sizes ranged from 628 to 1287. Comparison of mean
values shows no difference in the numbers of unique integration sites in SCID2 subjects
compared to SCID1 subjects (p=0.17).

Population sizes of progenitors were compared between SCID1 subjects who suffered
adverse events (F107, F110) versus those who did not (F102, F106), or versus SCID2
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subjects. Treating time points as independent tests, no systematic differences were
detected comparing within SCID1 subjects; a marginal difference was detected with a
comparison of adverse events versus no adverse events (adverse event samples compared
to pooled SCID1 and 2; p=0.041).

4.3.3. TCR-beta CDR3 analysis
Clonal structure of T-cell populations was investigated by analyzing TCR-beta
rearrangements in genomic DNA from blood CD3+ cells (Figure 2). CDR3 region
sequences were conceptually translated, and numbers of productive rearrangements
quantified (Figure 4-2A). For healthy adults, numbers ranged from 18,000 to 27,000 per
sample. For healthy children, numbers ranged from 18,000 to 22,000 per sample. For
SCID2, most samples were close to this range (12,000 to 33,000 per sample; no
significant difference in medians). For SCID1, results were slightly lower, with four out
of five samples between 15,000 and 23,000. The exceptional sample was from subject
F107, who suffered an adverse event and was treated by chemotherapy—in this case the
number was only 5,000 unique CDR3 sequences.

For all the CDR3 samples sequenced, the numbers of CDR3 clonotypes in the subject
were much larger than the numbers sequenced, so we used Chao 2 and replicate sampling
to estimate the number of CDR3 variants present. Estimators are sensitive to sampling
effort, so our estimates represent minimal values. Focusing on samples analyzed over
multiple replicates, we estimate population sizes of 26,000 to 2,600,000 CDR3 variants.
The median for SCID2 samples was not different from that of healthy children, but the
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median for SCID1 was significantly lower than for the healthy children (p=0.026;
Wilcoxon rank sum test).
Analysis of trends over time suggested that each subjects’ repertoire was becoming more
diverse (Figure 4-2B). The one exception was the unsuccessful case of reconstitution
(B205), which did not show longitudinal increase. Inferred CDR3 population sizes in
gene-corrected subjects approached or equaled sizes in healthy children, and exceeded
those in healthy adults.

To begin to characterize repertoire composition, we used Bray-Curtis dissimilarity and tSNE to cluster samples (Figure 4-2C). Replicates from each subject closely resembled
those from the same subject at different time points, but differed from other subjects. No
systematic differences were observed comparing SCID 1 and SCID2, or comparing either
data set to healthy controls.

Recombination involving the most frequently used V (Figure 4-2D) and J (Figure 4-2E)
gene segments was next quantified and compared. Usage of gene segments was
quantified for healthy children and averaged, then the profile was compared to genecorrected SCID subjects. The great majority of gene-corrected samples did not show
significant differences from the distribution in healthy children, both in the analysis of V
and J gene segment usage. The only exception was V gene usage in SCID2 subject
B201, where particularly early time point samples were available (6 and 12 months after
infusion of corrected cells). This subject was successfully corrected, so the unusual
distribution is not indicative of clinical failure. We speculate that at the very early time
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after gene correction newly produced T-cells are only beginning to be subjected to the
homeostatic mechanisms that yield the consistent mature repertoire. Figure 2F shows the
usage of V-J pairs within subjects, emphasizing the occasional outgrowth of expanded
clones, potentially in response to antigen, followed by down-modulation of abundance.
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Figure 4-2.
Analysis of TCRB CDR3 sequences. A) The unique numbers of rearranged genes detected are shown. The
colors indicate in frame rearrangements (blue), frameshifts (tan) and stop codons (red). B) Richness and
evenness of the inferred TCRB CDR3 populations. Patients are color coded as indicated on the right. The
ranges of healthy adults and children are shown by the grey and salmon shading, respectively. C)
Clustering of the samples sequenced using Bray-Curtis similarity and t-SNE. The association of patients
with samples is shown by the key at the right. D) V gene usage. The patient of origin is marked at the top
of each panel. E) J gene usage. F) Heat map summarizing the frequencies of utilization of the most
common V and J pairs. Subjects studied are marked at the top. Time of sampling is shown on the right.

4.3.4. Tracking T-cell ontogeny
Comparison of the estimated lower bound for the number of unique integration sites per
sample with the lower bound for the number of unique TCR sequences allows estimation
of a lower bound on the number of cell divisions required to generate the TCR-beta cell
population from gene-corrected precursors (Figure 4-3. We calculated the minimum
number of cell divisions as the base-2 logarithm of the difference between the estimated
population size of unique T cells and the estimated population size of integration sites:
CellDivisions = log 2 (TCRs − IntSites)
We found a relatively consistent range of minimum cell division values across patients
and timepoints, with a median of 8.41 and a minimum and maximum of 5.97 and 17.45.
Considering only the patients with successful, non-repeated therapy (B201, B203, and
B207), the range was tighter, with a median of 8.41 and a minimum and maximum of
5.97 and 14.72, respectively. The fraction of progenitor cells that die in the thymus is
unknown, so our estimates are lower bounds for the required number of cell divisions.

The highest values were for subject B205, for whom reconstitution was unsuccessful.
We speculate that homeostatic mechanisms may have resulted in signaling to a limited
number of progenitors to divide with increased frequency in this subject.
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Figure 4-3.
Minimum numbers of cell divisions between progenitors and daughter T cells. The x-axis shows time after
corrected cell infusion. The y-axis shows the estimated number of cell divisions calculated as described in
the text. The subjects studied are indicated beneath the figure as indicated by the color code.

4.3.5. Response of the microbiome to reconstitution
Microbiota community structure was analyzed for six gene-corrected subjects (Figure
4-4A) by extraction of DNA from swabs (oral and nasal samples) or stool (fecal samples)
followed by shotgun metagenomic sequencing. Numbers of samples available per
subject ranged from one to seven. The numbers of sequences acquired per sample
averaged 3,625,000 (oral), 72,000 (nasal) and 8,746,000 (fecal). Sequencing reads were
quality filtered as described in Methods and then assigned to microbial taxa using Kraken
(Wood & Salzberg, 2014) .
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The analysis of gut microbiota (Figure 4-4B) emphasized the differences between gut
microbiota of healthy children (left four columns) versus SCID gene-corrected subjects.
The healthy subjects were colonized predominantly with Bacteriodes, which is typical of
healthy gut, whereas the SCID-subjects showed a range of major colonists. B201 was
colonized mainly with Bifidobacteria, which is characteristic of healthy breast-fed babies
(Pannaraj et al., 2017). However, subjects B203 and B205 (early times) were colonized
with Veillonella, which is typically an oral bacteria, possibly indicative of colonization
with this organism along the length of the GI tract. Subject B204 showed high level
colonization with Enterobacteriaceae, typical of dysbiotic states. Early samples from
subjects B207 and F201 were dominated by viruses, even though whole stool was
sequenced, with infection by adenovirus and bocavirus respectively.

Oral samples from the healthy controls were dominated by typical oral bacteria, including
Prevotella, Streptococcus, Neisseria, and Haemophilus. In contrast, B203 at the earliest
time point was dominated by Bocavirus, B204 and B205 showed high level domination
by Streptococcus, and B207 was dominated by Rothia.

In nasopharyngeal samples, healthy subjects were dominated by Moraxella,
Staphylococcus and Propionibacterium. SCID subjects contained these lineages to
varying degrees, but also showed high level colonization by Streptococcus,
Corynebacterium, and others.
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Figure 4-4.
Longitudinal analysis of the microbiome during SCID-X1 gene correction. A) Timing of sample
acquisition. B) Longitudinal analysis of the nasopharyngeal microbiome. Each column indicates a sample.
Samples are grouped by subject as indicated at the top. Each row summarizes the proportions of a specific
microbial taxa inferred using Kraken. Abundance is color coded as indicated to the right. C) As in B, but
stool samples. D) As in B, but oropharyngeal samples.

We compared the full microbial compositions of the samples using Bray-Curtis
dissimilarities and found that the three sample types clustered by body site of origin
(Figure 4-5A, PERMANOVA p-value < 0.001). We also found that each subject
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clustered with themselves throughout all timepoints, reflecting consistently higher intersubject variability than intra-subject variability (PERMANOVA p-value < 0.001). In
several patients (B201, B205, and B207), the microbial communities began resembling
healthy children more at late times after cell infusion (Figure 4-5B), potentially reflecting
a combination of improving immune function and reduction in antibiotic usage.

Analysis of taxonomic richness provides insight into microbial community health, since
low richness is often associated with abnormal outgrowth of opportunistic organisms.
For stool, richness increased for 4/6 subjects over time, potentially indicative of
improving gut health (Figure 4-5C). Unexpectedly, of the four subjects for whom oral
samples were available, all showed abnormally low richness at every time point. For
many this was associated with particularly high Streptococcus colonization, an
observation that might be of interest to investigate further for possible clinical
implications. Nasopharyngeal microbiota showed richness comparable to healthy
controls.

SCID patients were treated with a wide variety of antibiotics before and after therapy to
mitigate opportunistic infections. To assess whether this was associated with an increase
in antibiotic resistance gene representation, we quantified antibiotic resistance genes in
the stool sequence samples using ShortBRED and the CARD antibiotic resistant factor
database (Figure 4-5D). We saw an increase in the total quantity of antibiotic resistance
genes. The SCID patients had a higher level of antibiotic resistance genes in their stool
than healthy subjects (pooled across timepoints, p = 0.048). These results indicate that the
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antibiotic regimen increases both general levels of antibiotic resistance genes. For patient
B201, who had a timepoint 24 months after therapy, the level of antibiotic resistance
genes decreased substantially between the 5 month and 24 month timepoint. At this
timepoint, the patient was no longer on any medications, which suggests that antibiotic
resistance gene load may decrease after treatment ceases.
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Figure 4-5.
Microbiome community analysis. A) Sample clustering using Bray-Curtis dissimilarity. Different sample
types are marked by the colors, healthy versus SCID are shown by the shapes. B) Comparison of stool
samples for each patient queried to healthy controls. Samples were clustered using Bray-Curtis
dissimilarity. Each panel compares one SCID subject samples (indicated at the top) to healthy control
samples (shown in grey). Elapsed time is shown using the color code (bottom). C) Representation of
selected antibiotic resistance genes in the three sample types studied. Each column indicates a
metagenomic data set from the subject listed at the top. Each row summarizes the abundance of an
antibiotic resistance gene class. The tiles are colored by reads per kilobase of target per million sequences
reads (RPKM); the color code is to the right of the panel.

4.3.6. Response of the virome
Viral particles were partially purified from stool, the DNA and RNA purified and
sequenced. Reads were assigned using Kraken, then extensive filtering was carried out to
remove contaminants and artifacts. Figure 4-6 shows the resulting attributions. For RNA
viruses, high level colonization was detected with astrovirus (B204 and B205) and
sapovirus (B203). For DNA viruses, numerous bacteriophage lineages were seen. For
viruses infecting animal cells, high levels of infection were seen for adenovirus in B201,
bocavirus in B203, and betatorquetenovirus (anellovirus) in B205. The adenovirus and
bocavirus infections diminished over time after successful gene correction.
Betatorquetenovirus is a normal commensal, and persisted.
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Figure 4-6.
Virome analysis. A) Heat map summarizing RNA viruses detected. Each column indicates a sample from
the patient indicated at the top of the heatmap, each row indicates a type of virus. The tiles are colored
according to proportion of total viral reads. B) Heat map summarizing DNA viruses detected. Markings as
in A.

4.4. Discussion
We present here a first look at the co-development of the microbiome and immune
system in patients after gene therapy for SCID. We used targeted sequencing of vector
integration sites to model the number of gene-corrected progenitor cells, and TCR
sequencing to capture the development of the T cell repertoire following therapy. The
combination of these data allowed a lower-bound approximation of the number of cell
divisions required to progress from a lymphopoetic stem cell to a circulating T cell, a
measurement uniquely possible thanks to gene marking by integration. We used shotgun
metagenomic sequencing in longitudinal samples to track early-term changes in the gut,
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oral and nasopharyngeal microbiome coincident with therapy. In a subset of these
timepoints, we purified and sequenced RNA and DNA viruses to show clearance of
pathogenic viruses with immune reconstitution and, in some patients, the presence of
viruses not reported in clinical records.

This estimate of cell divisions is limited by wide confidence intervals in the estimators
for unique TCRs and integration site population sizes, but despite that most of the
timepoints indicated roughly nine cell divisions between the progenitor stem cell and a
circulating T cell. This is a minimum value because the amount of cell death during Tcell ontogeny is unknown and likely high. This helps specify the functional capacity of
the lymphoid precursor cell targeted in initial transduction.

The microbiome analysis provided new evidence on how SCID gene therapy patients
progress to healthier phenotypes after successful therapy. Their immune cell diversity, as
measured by TCR sequencing, consistently moved from the oligoclonal range of older
adults and into a higher diversity range more characteristic of healthy children of that
age. Further, their overall circulating T cell richness showed a similar movement towards
a healthy and age-typical state. This is concordant with the observed results of healthy
immune function in these patients and shows that sequencing metrics of the T cell
repertoire correlate with clinical outcomes.

As in their immune repertoires, the microbiota of these patients changed in ways that
resembled the microbiomes of healthy children. We saw an increase in diversity and
richness of the microbes in the gut and oro- and nasopharygeal compartments and the
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outgrowth of bacteria associated with healthy gut function. In some patients, we were
also able to detect bacteria that may be associated with negative outcomes and antibiotic
resistance, potentially as a result of extended exposure to antibiotics and hospitalization.

An unexpected finding was the consistently low diversity of SCID oral samples, and the
high colonization with Streptococcus. It will be of interest to assess whether this is seen
in other immunodeficient subjects, and target investigations of possible oral pathology
associated with this organism.

In some of these patients, we found viruses known to cause enteropathic conditions in
humans, including astrovirus, bocavirus and adenovirus. In the case of patient B207, the
adenovirus detection was clinically corroborated with a diagnosis of adenoviremia. In
both, the viruses were cleared in later timepoints, likely as a result in part the newlyfunctioning immune system.

This study is also limited in a number of important ways. Most importantly, our sample
size was quite small. Moreover, clinical considerations often led to inconsistent
microbiome sampling based on patient and clinician availability, as sample collection
was a secondary concern to patient monitoring. As a result, our ability to make broad
inferences based on this sample set is limited.

Opportunities to study similar systems of immune system/microbiome dynamics are
present in SCID patients who undergo hematopoetic stem cell transplantation (HSCT). A
pilot study looking at the microbiome development in SCID patients after HSCT (Lane,
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2015) was also performed, though with 16S rRNA gene amplicon sequencing rather than
shotgun sequencing, no healthy controls, shorter sampling period, and no concurrent TCR
sequencing. They found inconsistent results in microbiome diversity after transplantation,
possibly due to the limited temporal range of the study, but did note that there were clear
differences in the microbiota before and after transplantation in the four subjects they
studied.

In summary, these data illustrate some of the uses of multi-omic data in assessing
outcome in human gene therapy. As more of these studies are carried out, it will be
possible to more fully assess the utility of such data. Of particular interest will be any
signatures that help forecast outcome and provide new opportunities for initiating specific
interventions.

4.5. Methods
4.5.1. Human subjects
Patients were recruited as described (M. Cavazzana-Calvo et al., 2000; Hacein-BeyAbina et al., 2014). We collected the same sample types from six healthy children
between the ages of 21-43 months under IRB 13-010072. We obtained sorted CD3+ T
cells from three anonymous healthy adult donors above the age of 18 from the Human
Immunology Core at the University of Pennsylvania. All samples were stored at -80oC.
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4.5.2. Integration site analytical methods
Integration site sequences were determined using two different methods due to changes in
technology over the period of patient monitoring. In the first, 454/Roche pyrosequencing
was used to determine integration site placement (G. P. Wang et al., 2007). In the
second, Illumina paired end sequencing was used (C. C. Berry et al., 2012; C. C. Berry et
al., 2017; Hacein-Bey Abina et al., 2015; Sherman et al., 2017). In both, DNA was
broken using shearing or restriction enzyme cleavage, then DNA adaptors ligated on to
the broken DNA ends. Nested PCR was then used to amplify from the linker to the
integrated vector, and the intervening segment of human DNA sequenced. All
integration site sequence analysis was be carried out in quadruplicate to minimize PCR
jackpotting. All sample sets were worked up together with human DNA lacking
integrated lentiviral sequences to monitor for PCR contamination, which was typically
undetectable. Different linkers were be used for ligation-mediated PCR for each sample
in a set to block PCR cross over. All samples were bar coded on both ends of the
molecule, and only those with correct bar code pairs analyzed, thereby suppressing
artifactual molecules resulting from PCR recombination. A total of 31 samples were
analyzed, yielding a total of 24,170 integration sites.

4.5.3. TCR sequence analysis
TCR sequencing was performed on whole blood samples that had been fractionated to
yied T cell (CD3+) or PBMC fractions. Genomic DNA was isolated and sequenced at
Adaptive Biotechnologies to determine CDR3 region sequences of the TCR beta locus
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(H. Robins et al., 2012). Data were analyzed using the immunoSeq Analyzer version 3.0.
A total of 40 samples were analyzed, yielding a total of 32 million TCRB sequences.

4.5.4. Microbiome sequencing
DNA was isolated from fecal, oral and nares samples using the following procedures:
Small aliquots of fecal material (<= 1ml) and the tips of each swab (for oral and nares
swabs) were deposited into a PowerSoil bead tube. DNA was extracted using standard the
MoBio PowerSoil DNA extraction protocol, with one or more blank extraction controls
worked up simultaneously with each set of samples. Work spaces were decontaminated
using bleach and UV irradiation. The resulting DNA from all samples and blank controls
was sequenced on an Illumina HiSeq 2500 using NextSeq chemistry and standard
Illumina dual barcoding for each sample.

Due to artifacts in genomic sequences for members of the Apicomplexa family, many
reads from a common water contaminant (Bradyrhizobium) were cross-annotated as
belonging to Apicomplexa. Consequently we removed all Bradyrhizobium and
Apicomplexa reads before further analysis due to their uncertain provenance.

4.5.5. Virome analytical methods
Viral particles were isolated from a subset of the fecal samples using a protocol adapted
from (Minot et al., 2013). Fecal samples were homogenized and filtered through a 0.4
micron filter. The filtered samples were then treated with DNaseI and RNAseI to remove
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exogenous nucleic acids. Combined nucleic acids were then purified from the sample
using the Qiagen UltraSens Virus Kit.

To obtain DNA viruses, we amplified viral genomes in an aliquot of the combined
nucleic acids using the Illustra Genomiphi V2 DNA amplification kit. Resulting
amplified DNA was quantified using PicoGreen and stored at -20oC. To obtain RNA
viruses, we treated a separate aliquot of the combined nucleic acids with DNAse+ and
then performed reverse transcription of the RNA to cDNA using the SuperScriptIII FirstStrand Synthesis System from Life Technologies and second strand synthesis using
Sequenase. The resulting cDNA was quantified with PicoGreen and stored at -20oC.

Resulting DNA was prepared and sequenced using NextSeq for library preparation and
an Illumina HiSeq 2500 for sequence acquisition. The same postprocessing pipeline was
used, including all quality-control, host removal, and read annotation steps. For analysis,
we considered only reads that fell under the Virus classification, and removed the
following viral annotations as being reagent contamination (Abbas et al., 2016; Clarke et
al., 2017): Enterobacteria phage M13, Enterobacteria phage T7, Enterobacteria phage
phiX-174 sensu lato, Bacillus phage phi29, and Pseudomonas phage phi6, human
herpesvirus 6 and 7, and Shamonda virus.
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4.5.6. Bioinformatic methods
To estimate population sizes of T cell progenitors from integration sites we used a
jackknifed Chao1 estimator (abundance-based), and for TCR sequence data, we used the
incidence-based Chao2 estimator (Chao, 1987).

Sequence reads for all metagenomic samples were processed using the Sunbeam pipeline
(https://github.com/eclarke/sunbeam). Reads were quality-controlled by trimming lowquality bases and adapter sequences using Trimmomatic (Bolger et al., 2014), and host
reads were removed using BWA (Li & Durbin, 2010). The remaining reads were filtered
for low-complexity sequences using dustmasker (Camacho et al., 2009) and Komplexity
(https://github.com/eclarke/komplexity). The reads that remained were assigned
taxonomy via Kraken (Wood & Salzberg, 2014) and a custom database built on all
microbial genomic sequences in RefSeq release 79 (O'Leary et al., 2016).

Antibiotic resistance gene levels were assessed using ShortBRED (Kaminski et al., 2015)
and a marker gene database built from CARD (Jia et al., 2017) available on the
ShortBRED website
(https://bitbucket.org/biobakery/shortbred/downloads/ShortBRED_CARD_2017_markers
.faa.gz). The same reads used as input to the Kraken taxonomic classifier were used as
input to ShortBRED.

Final analysis and figure generation was performed using the R statistical software (R
Core Team, 2017). Bray-Curtis dissimilarity and other ecological metrics were calculated
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using the R package vegan (Dixon, 2003). The full code listing and post-processed data
used for analysis and figures is available online at https://github.com/eclarke/scidmultiomics-paper.
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4.7. Supplemental Material
4.7.1. Supplemental Figures

Supp. Figure 4-1. PBMC samples timeline.

138

Supp. Figure 4-2. Genes near integration sites.
Stacked bar graphs summarizing genes at or near integration sites for each subject and sample studied here.
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Supp. Figure 4-3. TCRB population characteristics (PBMC).
Stacked bar graphs summarizing characteristics of the TCRB repertoire sequenced from PBMC cells.
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Supp. Figure 4-4. TCRB repertoire similarity (PBMC).
Bray-Curtis dissimilarity measurements for the TCRB repertoires sequenced from PBMC cells.
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Supp. Figure 4-5. Lymphocyte progenitor cell divisions.
Population size estimates for progenitors and daughter t cells, with the minimum number of doublings (cell
divisions) required.
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Supp. Figure 4-6. Mean read counts for metagenomic sequencing.

4.7.2. Supplemental Tables
All supplemental tables are attached in the Digital Supplement named
SupplementalTables.xlsx.

Supp. Table 4-1. Subjects in this study.
Supp. Table 4-2. Vector integration site data.
Supp. Table 4-3. TCR-beta repertoire data.
Supp. Table 4-4. Microbiome data
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Chapter 5. Conclusions and Future Directions
In this thesis I describe novel approaches to using metagenomic sequencing in idiopathic
and immune-related diseases. Metagenomics has found fruitful application in studies
involving gastrointestinal disorders and dysbiosis of existing communities. However, the
utility of metagenomics has been less clear in other types of diseases. The heightened
sensitivity of next-generation sequencing at retrieving rare microbes will be key to
uncovering causal pathogens in idiopathic diseases, but standard approaches suffer from
extreme sensitivity to contamination and false-positives (Lauder 2016). Meanwhile, the
interactions between microbiota and the immune system are beginning to be more clearly
understood (Arpaia 2013, Kamada 2014, Atarashi 2013) but their interplay in immune
disorders is less clearly defined.

In Chapter 2, I present a study where we looked for microbial triggers of sarcoidosis, a
granulomatous disease with no known cause. Our effort involved experimental and
statistical methods to rigorously account for environmental contamination. We collected
paired environmental controls for every sample and specific for every sample type: for
formalin-fixed, paraffin-embedded (FFPE) tissue we sampled the surrounding blank
paraffin, while for bronchoalveolar lavage (BAL) we sampled the prewash rinse of the
scope done prior to the procedure. These paired environmental controls were integrated
into the differential abundance testing by the use of a generalized linear mixed model
(GLMM) in which the background level of a taxa was allowed to vary in each sample
pair.
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This approach demonstrated exceptional precision in the face of strong environmental
covariates. We found that in one set of FFPE tissue samples, high levels of Aspergillus
fungi were present in sarcoidosis samples and not in healthy controls. But this same
difference was seen in the paired environmental controls, indicating that Aspergillus was
environmentally derived. (We later traced the source of this contamination back to
difference in storage sites between the two sample groups.) In studies without this
experimental design, we would have been unable to disentangle the environmental
confounder from the study group and spent significant time investigating Aspergillus
fungi as potential sarcoidosis triggers. However, differential abundance testing with the
GLMM did not identify Aspergillus as enriched. Rather, it identified a different fungus in
the Cladosporiaceae family as being enriched in sarcoidosis tissue over both healthy
tissue and the background environment. Cladosporiaceae fungi, while not known to be
pathogenic, are significant allergens and can cause disorders including hypersensitivity
pneumonitis (Chiba et al., 2009; Silva & Ekizlerian, 1985), so this is a biologically
plausible trigger in accordance with Relman’s postulates (Fredricks & Relman, 1996).

This paired environmental control study design and associated model are applicable to
other low-biomass metagenomic studies that aim to find differences between two groups.
While consensus has been reached on the necessity of blank controls in these studies to
characterize the input from reagents (Kim et al., 2017; Salter et al., 2014), those controls
alone are not always sufficient–for instance, they would not have uncovered the
Aspergillus contaminant as described above. There exist other approaches for
determining the source of microbial signatures in a sample (Knights et al., 2011), but this
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is the first able to translate these contaminating sources into terms that affect differential
abundance testing. Many clinical studies would benefit from this approach, especially
those that investigate microbial communities in sources previously considered sterile in
healthy individuals, such as the brain or placenta. In these studies, collection and storage
methods may contribute significant amounts of microbial biomass as a percentage of the
total. Without the controls, researchers may be erroneously reporting the presence of
endogenous or enriched microbiota when in fact they are subtle contaminants.

In Chapter 3 I describe a computational method that efficiently designs primers to
selectively amplify a target’s genome from a complex mixture. This program, swga,
makes the method described in (Leichy 2014) significantly more accessible to a broad
range of researchers. The wet-side method, selective whole-genome amplification
(SWGA), uses a set of phi29 primers that bind more frequently to a target’s genome than
the background to preferentially amplify the target using multiple-displacement
amplification. With the correct primers, the resulting amplicon will have much higher
amounts of target DNA proportionally than the starting mixture. Consequently, less
sequencing effort is required to achieve high depth-of-coverage of the target genome. The
swga program described in this chapter makes it possible to rapidly design primer sets for
this assay, which was originally a manual and error-prone process. The program works
by first identifying all k-mers of a range of lengths in the target and background genome.
It then filters the k-mers for undesirable characteristics including self-complementarity
and suboptimal melting temperature range, or uneven binding on the target genome. It
then assembles a graph representation with primers as vertices, and compatible primers–
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i.e. those that do not form primer dimers–are linked by edges. Each primer is weighted by
how frequently it binds the background genome. The program then searches for cliques,
or completely-interconnected subgraphs, with the smallest possible weight. These cliques
form the basis for selective primer sets for the SWGA method.

In this chapter, I demonstrated the efficacy of this program and approach on three reallife host/parasite systems. SWGA, when used with a well-chosen primer set, significantly
reduces the costs associated with repeatedly obtaining high-coverage genomes of a given
target. This is especially critical when retrieving genomes from targets that are difficult or
impossible to culture, especially in the context of pathogen or parasite genomics. In this
sense it is complementary to our efforts in Chapter 2 to identify microbial agents in
sarcoidosis: one possible use for SWGA is the isolation and characterization of the
precise Cladosporiaceae fungi in the sarcoidosis samples to see if there are strain-level
differences that may be causing disease symptoms.

In Chapter 4, I presented our efforts to characterize the interactions between the
microbiome and immune system of SCID patients after gene therapy. The gene therapy
trials for SCID provided a unique opportunity to observe a cohort of humans born
without an immune system, but with colonized microbiomes (normally, the microbiome
and immune systems co-develop in healthy babies). Once the gene therapy was
administered, these patients’ immune systems began to develop, and we were able to
track how the immune system and microbiome in these patients changed in response to
each other. To do this, we used T cell repertoire sequencing and metagenomic shotgun
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sequencing on a longitudinal sample set. We found that patients generally reconstituted a
normal-looking immune system when the therapy worked, which was concordant with
reported positive clinical outcome. We also found that patients’ microbiomes often
started off in a dysbiotic state, frequently characterized by the dominance of certain
bacteria or viruses, but shifted to resemble healthy children as time went on. We also
found that the microbiomes of these patients began to harbor higher levels of antibiotic
resistance genes as time went on, up until around six months post-therapy. This likely
correlates to high exposure levels of antibiotics administered prophylactically until the
patients were no longer immunocompromised (around six months post-therapy). We also
found high levels of adenovirus and astrovirus in these patients, which only occasionally
corresponded to clinical reports. In each case, high viral loads subsided with time,
indicating clearance of the virus.

This chapter demonstrated the potential applications for metagenomics in immune
diseases and gene therapy. Because of established links between the microbiome and
immune system, diseases that affect the immune system like SCID are likely to affect the
immune system (and vice versa). In SCID patients, we were unsure whether immune
system restoration would lead to restoration of a normal microbiome, or if a dysbiotic
state would persist due to a founder-type effect. In the patients for which we had the
longest sampling time course, we did see a normalization of the microbiome and decrease
of antibiotic resistance load after immune reconstitution. While this conclusion is limited
by the small number of patients, it suggests that the immune system acts to maintain a
healthy microbial community in these patients.
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Future directions
The work presented in this thesis center around the use of metagenomic sequencing in a
variety of diseases. I explored the use of sequencing to robustly identify triggers in
sarcoidosis, efficiently isolate difficult-to-culture pathogen genomes such as
Mycobacterium tuberculosis using SWGA, and characterize microbe-immune
interactions in SCID after gene therapy. These works center around short-read
sequencing, the current state-of-the-art sequencing method used today for metagenomics.
However, it seems likely that this will soon be supplanted by rising long-read
technologies, such as those from Pacific Biosciences and Oxford Nanopore.

The essence of nanopore long-read sequencing is a small pore that moves nucleotide
molecules through a few bases at a time and measures changes in the electrical potential
based on the sequence. It avoids issues inherent to Illumina chemistry that lead to high
error rates with longer sequences, and consequently can read tens of kilobases in length
per sequence (under optimal conditions). However, nanopore sequencing comes with its
own drawbacks, including a higher error rate and more difficult-to-model error profile.
Even in the last few years, however, the error rates have decreased substantially and it
seems reasonable to expect them to continue falling. Another key benefit of nanopore
sequencing, specific to the Oxford minION, is the extremely small size of the sequencer
itself. It is only slightly larger than a thumb drive and connects to a computer using USB.
This small size raises alluring potential for field deployment as part of a portable
sequencing and analysis toolkit.
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Metagenomically, long-read sequencing offers a number of advancements over current
methods. First, the retrieval of long contiguous DNA allows us to fill in the gaps and
reconstruct microbial genomes much more easily (Loman, Quick, & Simpson, 2015;
Quick et al., 2017). More comprehensive microbial genome databases will significantly
improve our ability to classify and functionally annotate microbiomes. Second, long
reads offer the ability to recover strain-level resolution in tagged sequencing experiments.
While we are nominally constrained to tagged sequences smaller than 500bp in Illumina
paired-end sequencing, long reads would enable the recovery of the entire 16S or ITS
region and significantly improve our phylogenetic resolution (Kerkhof, Dillon,
Häggblom, & McGuinness, 2017). Third, it opens up new opportunities for
biosurveillance. Assuming we could identify a specific sequence unique to a pathogen or
virulence gene of interest, long read sequencers can “read until” detection of that
sequence (Loose, Malla, & Stout, 2016). Paired with a potentially field-deployable
sequencer, this could enable extremely rapid monitoring of an environment for pathogens
and antibiotic resistance capabilities, without the need for culture, extensive
bioinformatics analysis, or data storage.

Even considering our current approaches in short-read sequencing, there remains
significant room for advancement from the techniques outlined in this thesis.
Metagenomic sequencing is exquisitely sensitive, but this can result in a higher level of
false positives and spurious detections. In Chapter 2, I outlined an experimental approach
that helps assuage these problems, but there are situations in which environmental
controls may not be identifiable or obtainable. Approaches that restrict DNA to just those
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from viable organisms may be worthwhile in certain studies (Emerson et al., 2017) but
often samples are collected and stored in ways that damage or kill the microbes in them.
Other ways of reducing spurious detections include the use of RNA in conjunction with
DNA, on the premise that RNA is more readily degraded in the environment due to
ubiquitous RNase activity. Making cDNA libraries from RNA and comparing to the
results from gDNA could identify signatures from only authentically-present microbes in
the original sample.

It is likely that metagenomic sequencing will become a core part of diagnostic and
clinical work in time, but it has some way to go before it reaches the necessary level of
affordability, speed and rigor. The promise of rapid, unbiased detection of any microbe or
gene in a sample is one that could revolutionize our ability to track pathogens and disease
outbreaks. Similarly, integration of metagenomic sequencing with new advancements in
immunological sequencing will allow us to more effectively treat and understand
immunological diseases. In total, the work demonstrated in this thesis lays a foundation
for more robust and informative uses of metagenomic sequencing in the study of
idiopathic and immunological disorders.
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